<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nortriptyline: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nortriptyline: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Nortriptyline: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9711" href="/d/html/9711.html" rel="external">see "Nortriptyline: Drug information"</a> and <a class="drug drug_patient" data-topicid="10917" href="/d/html/10917.html" rel="external">see "Nortriptyline: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709176"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Suicidality in children and adolescents:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants increased the risk compared with placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of nortriptyline or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared with placebo in adults older than 24 years; there was a reduction in risk with antidepressants compared with placebo in adults 65 years and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Appropriately monitor patients of all ages who are started on antidepressant therapy and observe them closely for clinical worsening, suicidality, or unusual changes in behavior. Advise families and caregivers of the need for close observation and communication with the health care provider. Nortriptyline is not approved for use in pediatric patients.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F202713"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Pamelor</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867729"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Nortriptyline;</li>
<li>Aventyl</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1054497"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidepressant, Tricyclic (Secondary Amine)</span></li></ul></div>
<div class="block dop drugH1Div" id="F52812540"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc8a7e32-2b4e-402d-ae6a-0c132cdad29a">Attention-deficit/hyperactivity disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Attention-deficit/hyperactivity disorder (ADHD):</b> Limited data available: <b>Note:</b> Should not be used first-line; use should be reserved for cases where other therapies have failed or not tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17581453','lexi-content-ref-15998933']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17581453','lexi-content-ref-15998933'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: Oral: Initial: 0.5 mg/kg/day; may increase by 0.5 mg/kg/day increments at weekly intervals; maximum daily dose: 2 mg/kg/<b>day</b> up to 100 mg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17581453','lexi-content-ref-11052409','lexi-content-ref-8919704','lexi-content-ref-8444763']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17581453','lexi-content-ref-11052409','lexi-content-ref-8919704','lexi-content-ref-8444763'])">Ref</a></span>); in one trial, the daily dose was divided twice daily with a dose administered before school and a dose after dinner; reported mean effective dose: 1.8 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11052409']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11052409'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="88439bfa-09ac-4e07-b39c-4a2d64805a79">Enuresis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Enuresis:</b> Limited data available: <b>Note:</b> Due to the risk of serious side effects (eg, arrhythmias, heart block, seizures), TCAs are considered third line treatment for enuresis; may consider use in patients who have failed all other therapies; high relapse rate when discontinued (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22168597','lexi-content-ref-Gal.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22168597','lexi-content-ref-Gal.2007'])">Ref</a></span>). Administer dose 30 minutes before bedtime; usual treatment duration: ≤3 months.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: Oral: General dosing: Initial: 10 to 20 mg/day; titrate up to maximum daily dose of 40 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gal.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gal.2007'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ae35da88-7e3c-40ea-9daa-1be1ccfd22b6">Depression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Depression:</b> Oral: <b>Note:</b> Controlled clinical trials have not shown tricyclic antidepressants to be superior to placebo for the treatment of depression in children and adolescents; not recommended as first line medication; may be beneficial for patient with comorbid conditions (ADHD enuresis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18049300','lexi-content-ref-16434782','lexi-content-ref-15908090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18049300','lexi-content-ref-16434782','lexi-content-ref-15908090'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to 12 years: Limited data available: 1 to 3 mg/kg/day in 4 divided doses; maximum daily dose: 150 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gal.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gal.2007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: 30 to 50 mg/day in 3 to 4 divided doses or as a single daily dose; maximum daily dose: 150 mg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="393e56f7-bded-45b3-b486-3009d2e7543b">Neuropathic pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuropathic pain:</b> Limited data available: Children and Adolescents: Oral: Usual range: 0.05 to 1 mg/kg/dose at bedtime; begin at the lower end of dosing range and titrate every 3 days to effect; the analgesic effects of TCA's are typically observed at a lower dose compared to TCA doses for depression; maximum daily dose: 3 mg/kg/<b>day</b> or 150 mg/<b>day</b>, whichever is less (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APS.1','lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APS.1','lexi-content-ref-Kliegman.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> Consider planning antidepressant discontinuation for lower-stress times, recognizing non-illness-related factors could cause stress or anxiety and be misattributed to antidepressant discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29337001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29337001'])">Ref</a></span>). Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of discontinuation syndromes (withdrawal) and allow for the detection of reemerging disease state symptoms (eg, relapse). Evidence supporting ideal taper rates after illness remission is limited. APA and NICE guidelines suggest tapering therapy over at least several weeks with consideration to the half-life of the antidepressant; antidepressants with a shorter half-life may need to be tapered more conservatively. After long-term (years) antidepressant treatment, WFSBP guidelines recommend tapering over 4 to 6 months, with close monitoring during and for 6 months after discontinuation. If intolerable discontinuation symptoms occur following a dose reduction, consider resuming the previously prescribed dose and/or decrease dose at a more gradual rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.1','lexi-content-ref-12479080','lexi-content-ref-19621834','lexi-content-ref-11347722','lexi-content-ref-22132433','lexi-content-ref-16683860','lexi-content-ref-15014601','lexi-content-ref-16913164']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.1','lexi-content-ref-12479080','lexi-content-ref-19621834','lexi-content-ref-11347722','lexi-content-ref-22132433','lexi-content-ref-16683860','lexi-content-ref-15014601','lexi-content-ref-16913164'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>MAO inhibitor recommendations:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Switching to or from an MAO inhibitor intended to treat psychiatric disorders:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of nortriptyline.</p>
<p style="text-indent:-2em;margin-left:6em;">Allow 14 days to elapse between discontinuing nortriptyline and initiation of an MAO inhibitor intended to treat psychiatric disorders.</p></div>
<div class="block dorp drugH1Div" id="F52729798"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Not dialyzable. There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F52729799"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Adolescents: Use lower doses and slower titration; individualization of dosage is recommended.</p></div>
<div class="block doa drugH1Div" id="F202717"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9711" href="/d/html/9711.html" rel="external">see "Nortriptyline: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> In patients sensitive to adverse effects, some experts suggest lower starting doses of 10 mg daily and gradual titration (eg, at intervals ≥1 week) unless otherwise specified (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.3'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9fc78923-c3d1-4aa8-9d26-05bc0308cd04">Cyclic vomiting syndrome, moderate to severe, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cyclic vomiting syndrome, moderate to severe, prevention (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used as an alternative to amitriptyline to minimize adverse effects. Use and dosing established with amitriptyline; nortriptyline doses are equivalent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Li.1','lexi-content-ref-31241819']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Li.1','lexi-content-ref-31241819'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Initial: 10 to 25 mg once daily at bedtime; may increase dose based on response and tolerability in increments of 10 to 25 mg at weekly intervals up to 100 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36791365','lexi-content-ref-20027010','lexi-content-ref-31241819']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36791365','lexi-content-ref-20027010','lexi-content-ref-31241819'])">Ref</a></span>). Typically requires a trial of 1 to 2 months at a therapeutic dose to adequately assess efficacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Li.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Li.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98364f85-c921-4565-8d52-e57d073319cb">Functional dyspepsia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Functional dyspepsia (alternative agent) (off-label use)</b>: <b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May be used to augment or replace proton pump inhibitor therapy in partial and nonresponders who have been tested for <i>H. pylori </i>and treated if positive (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28631728','lexi-content-ref-Longstreth.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28631728','lexi-content-ref-Longstreth.1'])">Ref</a></span>). Use and dosing established with amitriptyline; nortriptyline doses are equivalent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21767283','lexi-content-ref-25921377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21767283','lexi-content-ref-25921377'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Initial: 10 to 25 mg once daily at bedtime; may increase dose based on response and tolerability in increments of 10 to 25 mg at ≥1-week intervals, up to a maximum of 50 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21767283','lexi-content-ref-Longstreth.1','lexi-content-ref-25921377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21767283','lexi-content-ref-Longstreth.1','lexi-content-ref-25921377'])">Ref</a></span>). Some experts suggest a lower maintenance dose range of 20 to 30 mg/day. Typically requires a trial of 8 to 12 weeks at a therapeutic dose to adequately assess efficacy. If effective, reassess at 6 months and consider tapering; may resume if dyspepsia recurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Longstreth.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Longstreth.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d5d93c56-6224-41c6-952f-3cee22bf59b2">Headache, chronic tension-type, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Headache, chronic tension-type, prevention (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Use and dosing established with amitriptyline; nortriptyline doses are equivalent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8795600','lexi-content-ref-11325322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8795600','lexi-content-ref-11325322'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral</b>: Initial: 10 to 25 mg once daily at bedtime; may increase dose based on response and tolerability in 10 to 25 mg increments at intervals ≥1 week, up to a maximum of 125 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8795600','lexi-content-ref-20482606','lexi-content-ref-11325322','lexi-content-ref-25921377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8795600','lexi-content-ref-20482606','lexi-content-ref-11325322','lexi-content-ref-25921377'])">Ref</a></span>). May require up to 12 weeks of treatment at a therapeutic dose to adequately assess efficacy. Once effective, continue for at least 3 to 6 months before attempting gradual tapering (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25921377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25921377'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="26f7a22c-ee50-4e23-b841-1f376359ef97">Irritable bowel syndrome–associated pain and global symptoms</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Irritable bowel syndrome–associated pain and global symptoms (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Due to their effect on intestinal transit, tricyclic antidepressants should be used cautiously in patients with constipation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35738724']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35738724'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 10 to 25 mg once daily at bedtime; may gradually increase dose based on response and tolerability to a recommended dose of 25 to 75 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33315591']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33315591'])">Ref</a></span>). Some experts recommend 3 to 4 weeks of therapy before increasing the dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wald.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cf110575-e58e-40d7-bc64-ed5b385ce732">Major depressive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar) (alternative agent): Oral: </b>Initial: 25 to 50 mg once daily at bedtime; increase dose based on response and tolerability in 25 to 50 mg increments at intervals ≥1 week up to a usual dose of 50 to 150 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.1','lexi-content-ref-Hirsch.3','lexi-content-ref-VADoD.1','lexi-content-ref-23879318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.1','lexi-content-ref-Hirsch.3','lexi-content-ref-VADoD.1','lexi-content-ref-23879318'])">Ref</a></span>). To improve tolerability, some experts suggest an initial dose of 25 mg/day at bedtime for most patients; a higher starting dose of 50 mg/day and more rapid titration (eg, every few days) may be considered in closely supervised (eg, hospitalized) settings (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.3'])">Ref</a></span>). Maximum: 150 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>); however, some patients tolerate and benefit from doses up to 200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.1','lexi-content-ref-Hirsch.3','lexi-content-ref-23879318','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.1','lexi-content-ref-Hirsch.3','lexi-content-ref-23879318','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="683d5204-2f9a-4f90-86f2-dc2acc899423">Migraine, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, prevention (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> An adequate trial for assessment of effect is considered to be at least 2 to 3 months at a therapeutic dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31113373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31113373'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Initial: 10 to 25 mg once daily at bedtime; increase dose based on response and tolerability in 10 mg increments at intervals of 1 to 2 weeks, up to 100 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30895388','lexi-content-ref-22683887','lexi-content-ref-31113373','lexi-content-ref-35037597']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30895388','lexi-content-ref-22683887','lexi-content-ref-31113373','lexi-content-ref-35037597'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="33da3206-1780-49f6-8ed0-58b616ea7ab4">Myofascial pain syndrome and related causes of chronic pain including myofascial pelvic pain, nonradicular neck pain, temporomandibular disorders, and vulvodynia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myofascial pain syndrome and related causes of chronic pain including myofascial pelvic pain, nonradicular neck pain, temporomandibular disorders, and vulvodynia (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May consider for patients with persistent symptoms despite multimodal care and treatment with first-line agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9586488']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9586488'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 10 to 25 mg once daily at bedtime; may increase based on response and tolerability in 10 to 25 mg increments every 1 to 2 weeks to a usual dosage range of 25 to 75 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25905532','lexi-content-ref-9586488']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25905532','lexi-content-ref-9586488'])">Ref</a></span>). Maximum: 150 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9586488','lexi-content-ref-Spadt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9586488','lexi-content-ref-Spadt.1'])">Ref</a></span>). Due to tolerability concerns, some experts avoid or use caution with doses &gt;50 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Isaac.1','lexi-content-ref-Mehta.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Isaac.1','lexi-content-ref-Mehta.1'])">Ref</a></span>). May require 6 to 12 weeks of therapy (including 2 weeks at maximum tolerated dose) to adequately assess efficacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mehta.1','lexi-content-ref-Tauben.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mehta.1','lexi-content-ref-Tauben.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b2c63bc5-d06b-49a9-9108-d90e6cbccee2">Neuropathic pain, chronic, including diabetic neuropathy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuropathic pain, chronic, including diabetic neuropathy (off-label use):</b>
<b>Oral:</b> Initial: 10 to 25 mg once daily at bedtime; may increase dose based on response and tolerability in 10 to 25 mg increments at intervals ≥1 week, up to a usual dosage range of 25 to 100 mg once daily at bedtime or in 2 divided doses. Maximum dose: 150 mg/day given once daily at bedtime or in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27999003','lexi-content-ref-19796802','lexi-content-ref-17182183','lexi-content-ref-23937282','lexi-content-ref-17372630','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27999003','lexi-content-ref-19796802','lexi-content-ref-17182183','lexi-content-ref-23937282','lexi-content-ref-17372630','lexi-content-ref-manu.1'])">Ref</a></span>). In patients with diabetic neuropathy, some experts recommend a maximum dose of 100 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Feldman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Feldman.1'])">Ref</a></span>). May require 6 to 12 weeks of therapy (including 2 weeks at maximum tolerated dose) to adequately assess efficacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Tauben.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Tauben.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cd263141-59d9-4f4b-8e26-25d16a66c401">Postherpetic neuralgia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postherpetic neuralgia (alternative agent) (off-label use):</b>
<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May consider for patients who do not tolerate or respond to a gabapentinoid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ortega.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ortega.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 10 to 20 mg once daily at bedtime; may increase daily dose based on response and tolerability in 10 to 20 mg increments at intervals of ≥3 days (typically weekly) to a maximum dose of 150 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12370455','lexi-content-ref-9781549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12370455','lexi-content-ref-9781549'])">Ref</a></span>). May require 6 to 12 weeks of therapy (including 2 weeks at maximum tolerated dose) to adequately assess efficacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Tauben.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Tauben.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e049a955-ebdd-4184-a38a-1676817bbf2f">Smoking cessation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Smoking cessation</b>
<b>(alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May consider, in conjunction with behavioral support, for patients who do not tolerate first-line agents or who require an adjunct to first-line therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>). Initiate ≥2 weeks before planned quit date (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9707377','lexi-content-ref-12365880','lexi-content-ref-15514412','lexi-content-ref-9778204','lexi-content-ref-15534159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9707377','lexi-content-ref-12365880','lexi-content-ref-15514412','lexi-content-ref-9778204','lexi-content-ref-15534159'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Days 1 to 3: <b>Oral: </b>25 mg once daily at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9707377','lexi-content-ref-12365880','lexi-content-ref-15514412','lexi-content-ref-9778204']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9707377','lexi-content-ref-12365880','lexi-content-ref-15514412','lexi-content-ref-9778204'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Days 4 to 7: <b>Oral: </b>50 mg once daily at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9707377','lexi-content-ref-12365880','lexi-content-ref-15514412','lexi-content-ref-9778204']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9707377','lexi-content-ref-12365880','lexi-content-ref-15514412','lexi-content-ref-9778204'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance </i>(day 8 and later): <b>Oral: </b>75 mg once daily at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9778204']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9778204'])">Ref</a></span>). Some patients may experience improved tolerability by administering in 2 or 3 divided doses. Further titration up to 125 mg/day may be needed to adequately decrease cravings in some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9707377','lexi-content-ref-12365880','lexi-content-ref-15514412']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9707377','lexi-content-ref-12365880','lexi-content-ref-15514412'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration:</i> Continue for a total of at least 12 weeks of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9707377','lexi-content-ref-12365880','lexi-content-ref-15534159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9707377','lexi-content-ref-12365880','lexi-content-ref-15534159'])">Ref</a></span>). May consider extended maintenance therapy (eg, up to 1 year) based on individualized risk-benefit assessment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15514412']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15514412'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Discontinuation of therapy:</i></b> In general, when discontinuing antidepressant treatment that has lasted for &gt;3 weeks, gradually taper the dose (eg, over 2 to 4 weeks) to minimize withdrawal symptoms and detect reemerging symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.1','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.1','lexi-content-ref-25677972'])">Ref</a></span>). Reasons for a slower taper (eg, over ≥4 weeks) include a history of antidepressant withdrawal symptoms or high doses of antidepressants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.1','lexi-content-ref-Hirsch.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.1','lexi-content-ref-Hirsch.1'])">Ref</a></span>). If intolerable withdrawal symptoms occur, resume the previously prescribed dose and/or decrease dose at a more gradual rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15014601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15014601'])">Ref</a></span>). Select patients (eg, those with a history of discontinuation syndrome) on long-term treatment (&gt;6 months) may benefit from tapering over &gt;3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25677972'])">Ref</a></span>). Evidence supporting ideal taper rates is limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15014601','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15014601','lexi-content-ref-25677972'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Switching antidepressants: </i></b>Evidence for ideal antidepressant switching strategies is limited; strategies include cross-titration (gradually discontinuing the first antidepressant while at the same time gradually increasing the new antidepressant) and direct switch (abruptly discontinuing the first antidepressant and then starting the new antidepressant at an equivalent dose or lower dose and increasing it gradually). Cross-titration (eg, over 1 to 4 weeks depending upon sensitivity to discontinuation symptoms and adverse effects) is standard for most switches but is contraindicated when switching to or from a monoamine oxidase inhibitor (MAOI). A direct switch may be an appropriate approach when switching to another agent in the same or similar class (eg, when switching between 2 selective serotonin reuptake inhibitors), when the antidepressant to be discontinued has been used for &lt;1 week, or when the discontinuation is for adverse effects. When choosing the switch strategy, consider the risk of discontinuation symptoms, potential for drug interactions, other antidepressant properties (eg, half-life, adverse effects, pharmacodynamics), and the degree of symptom control desired (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2','lexi-content-ref-23459282','lexi-content-ref-23879318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2','lexi-content-ref-23459282','lexi-content-ref-23879318'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Switching to or from an MAOI:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Allow 14 days to elapse between discontinuing an MAOI and initiation of nortriptyline.</p>
<p style="text-indent:-2em;margin-left:6em;">Allow 14 days to elapse between discontinuing nortriptyline and initiation of an MAOI.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990581"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7248140','lexi-content-ref-22859791']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7248140','lexi-content-ref-22859791'])">Ref</a></span>); however, interindividual variability in clearance and half-life is high (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7248140']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7248140'])">Ref</a></span>); use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not dialyzed: No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7105623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7105623'])">Ref</a></span>); however, dialysis patients have demonstrated increased sensitivity to the anticholinergic effects of tricyclic antidepressants (TCAs). Use with caution along with close monitoring for both anticholinergic and QT-prolonging effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25857865','lexi-content-ref-3971655','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25857865','lexi-content-ref-3971655','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (large V<sub>d</sub>): No dosage adjustment necessary (expert opinion); however, dialysis patients have demonstrated increased sensitivity to the anticholinergic effects of TCAs. Use with caution along with close monitoring for both anticholinergic and QT-prolonging effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25857865','lexi-content-ref-3971655','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25857865','lexi-content-ref-3971655','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>Unlikely to be dialyzed: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Unlikely to be dialyzed: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987940"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. Nortriptyline is metabolized hepatically; use with caution. Some experts recommended reducing initial and maintenance doses by 50% in patients with hepatic impairment, with cautious dose adjustments based on response and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25248846','lexi-content-ref-25175904']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25248846','lexi-content-ref-25175904'])">Ref</a></span>).</p></div>
<div class="block arsc drugH1Div" id="F55765458"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Anticholinergic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Nortriptyline may cause anticholinergic effects, such as <b>constipation</b>, <b>xerostomia</b>, <b>blurred vision</b>, <b>palpitations</b>, <b>tachycardia</b>, and <b>urinary retention</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21332244','lexi-content-ref-10607968','lexi-content-ref-2521060','lexi-content-ref-9699704','lexi-content-ref-28769859','lexi-content-ref-9159697']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21332244','lexi-content-ref-10607968','lexi-content-ref-2521060','lexi-content-ref-9699704','lexi-content-ref-28769859','lexi-content-ref-9159697'])">Ref</a></span>). Drugs with anticholinergic effects may increase the risk of falls in older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25735839']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25735839'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; binding affinity to the muscarinic receptor(s), permeability of the blood-brain barrier, and serum and tissue concentrations all influence the risk of anticholinergic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25735839']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25735839'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9699704','lexi-content-ref-Riedel.1','lexi-content-ref-11250852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9699704','lexi-content-ref-Riedel.1','lexi-content-ref-11250852'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9699704','lexi-content-ref-Riedel.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9699704','lexi-content-ref-Riedel.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of drugs with anticholinergic properties (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18510583','lexi-content-ref-Riedel.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18510583','lexi-content-ref-Riedel.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific tricyclic antidepressants: Nortriptyline is considered to display modest to moderate anticholinergic activity at typical doses compared to agents with high anticholinergic effects, such as amitriptyline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18510583','lexi-content-ref-Riedel.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18510583','lexi-content-ref-Riedel.1'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cardiac conduction abnormalities</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Tricyclic antidepressants (TCAs), including nortriptyline, are associated with cardiotoxicity, particularly at supratherapeutic doses. At therapeutic doses, TCAs can cause slowing of intraventricular conduction, manifested by prolonged PR, QRS, and QT intervals on ECG in children, adolescents, and adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15320756','lexi-content-ref-8936916']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15320756','lexi-content-ref-8936916'])">Ref</a></span>). <b>Sinus tachycardia</b> and potentially life-threatening ventricular arrhythmias, or <b>heart block</b> leading to sudden cardiac death are associated with supratherapeutic doses or therapeutic doses in select patients with severe heart disease or preexisting conduction disorders (eg, Brugada syndrome or bundle branch block, long QT syndrome) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25444490','lexi-content-ref-23425522','lexi-content-ref-25272563','lexi-content-ref-8444830','lexi-content-ref-15001975','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25444490','lexi-content-ref-23425522','lexi-content-ref-25272563','lexi-content-ref-8444830','lexi-content-ref-15001975','lexi-content-ref-32929996'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related (some mechanisms); at therapeutic doses, TCAs inhibit sodium channel conduction, potentially delaying cardiac depolarization and causing prolongation of the QRS complex on ECG. Multiple other mechanisms contribute to the cardiac effects associated with TCAs, including inhibition of central cholinergic neurotransmission (potentially causing tachycardia), norepinephrine reuptake inhibition (potentially exacerbating tachycardia), and blockade of alpha-adrenergic receptors (potentially lowering systemic vascular resistance and causing hypotension or orthostatic hypotension). In addition, high doses increase sympathetic and decrease parasympathetic effects on heart rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15320756','lexi-content-ref-22936860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15320756','lexi-content-ref-22936860'])">Ref</a></span>). Sinus tachycardia is attributed to the inhibition of norepinephrine and nortriptyline's anticholinergic action (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6407505','lexi-content-ref-28709467']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6407505','lexi-content-ref-28709467'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Increased age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22936860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22936860'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22936860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22936860'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypokalemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22936860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22936860'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Coronary artery disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25065442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25065442'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Coadministration of drugs independently associated with QT interval prolongation or further increase risk of arrhythmia (nortriptyline shares electrophysiologic properties of type IA antiarrhythmics such as quinidine, procainamide, and disopyramide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8444830','lexi-content-ref-15320756','lexi-content-ref-22936860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8444830','lexi-content-ref-15320756','lexi-content-ref-22936860'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting conduction disease, particularly bundle branch block or Brugada syndrome, or family history of congenital long QT syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15320756','lexi-content-ref-32929996','lexi-content-ref-22936860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15320756','lexi-content-ref-32929996','lexi-content-ref-22936860'])">Ref</a></span>). <b>Note</b>: Use is relatively contraindicated in patients with conduction abnormalities.</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses, particularly in children (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15320756']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15320756'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS depression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Tricyclic antidepressants (TCAs), including nortriptyline, may cause dose-dependent CNS depression, including <b>dizziness</b>, <b>drowsiness</b>, <b>ataxia</b>, <b>cognitive dysfunction </b>(particularly in older adults), <b>confusion</b>,<b> disorientation</b>, <b>fatigue</b>, and <b>psychomotor impairment</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Biringer.2009','lexi-content-ref-18510583','lexi-content-ref-21332244','lexi-content-ref-2376622','lexi-content-ref-21716778','lexi-content-ref-7803947','lexi-content-ref-9159697','lexi-content-ref-25735839','lexi-content-ref-11250852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Biringer.2009','lexi-content-ref-18510583','lexi-content-ref-21332244','lexi-content-ref-2376622','lexi-content-ref-21716778','lexi-content-ref-7803947','lexi-content-ref-9159697','lexi-content-ref-25735839','lexi-content-ref-11250852'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; drowsiness and psychomotor effects are due to anticholinergic and antihistaminergic properties of TCAs, with varying degrees of effects depending on the specific agent. TCAs also produce alpha-adrenergic blockade which can contribute to sedation and dizziness (from orthostatic hypotension) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Biringer.2009','lexi-content-ref-18510583','lexi-content-ref-21716778','lexi-content-ref-2140373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Biringer.2009','lexi-content-ref-18510583','lexi-content-ref-21716778','lexi-content-ref-2140373'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; difficult to define; some symptoms may occur with first dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors (TCAs in general):</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant alcohol</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant CNS depressants (eg, anticholinergics, antihistamines) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2140373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2140373'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2140373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2140373'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18510583','lexi-content-ref-7803947','lexi-content-ref-25735839','lexi-content-ref-11250852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18510583','lexi-content-ref-7803947','lexi-content-ref-25735839','lexi-content-ref-11250852'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Increased TCA plasma levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2140373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2140373'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific TCA: Nortriptyline is associated with a low propensity for causing sedation relative to TCAs associated with high levels of sedation, such as amitriptyline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Biringer.2009']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Biringer.2009'])">Ref</a></span>). Nortriptyline is associated with a modest to moderate propensity for producing anticholinergic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18510583','lexi-content-ref-Riedel.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18510583','lexi-content-ref-Riedel.1'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Fractures</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants have been associated with an increased risk of falls and bone fractures in observational studies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17242321','lexi-content-ref-22659406']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17242321','lexi-content-ref-22659406'])">Ref</a></span>). Tricyclic antidepressants (TCAs) have also been associated with an increased fracture risk; however, risk varies by agent and the evidence is conflicting, particularly with nortriptyline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12835289','lexi-content-ref-22638709','lexi-content-ref-22659406','lexi-content-ref-18219438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12835289','lexi-content-ref-22638709','lexi-content-ref-22659406','lexi-content-ref-18219438'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not fully elucidated; per selective serotonin reuptake inhibitor-derived literature, may be related to a direct effect on bone metabolism via interaction with 5-HT and osteoblast, osteocyte, and/or osteoclast activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22659406','lexi-content-ref-30775508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22659406','lexi-content-ref-30775508'])">Ref</a></span>). Of note, nortriptyline is associated with low 5-HT (serotonin) transporter inhibition compared to its effect on norepinephrine inhibition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22659406']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22659406'])">Ref</a></span>). Fall risk with TCAs may also be attributed to sedation, syncope, orthostatic hypotension, and/or confusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22638709','lexi-content-ref-25735839','lexi-content-ref-11250852','lexi-content-ref-18219438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22638709','lexi-content-ref-25735839','lexi-content-ref-11250852','lexi-content-ref-18219438'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Intermediate; observational studies suggest the increased fracture risk observed with TCAs occurs early and reaches a peak within 1 month of initiation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22659406']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22659406'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors (TCAs in general):</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use with other agents that may further affect physical balance and contribute to falls (eg, anxiolytics) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18219438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18219438'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyponatremia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Tricyclic antidepressants (TCAs), including nortriptyline, have been rarely associated with syndrome of inappropriate antidiuretic hormone secretion (<b>SIADH</b>) and/or hyponatremia, predominately in the elderly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25262043','lexi-content-ref-28923523','lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25262043','lexi-content-ref-28923523','lexi-content-ref-24094459'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> May cause SIADH via release of antidiuretic hormone (ADH) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25262043']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25262043'])">Ref</a></span>) or may cause nephrogenic SIADH by increasing the sensitivity of the kidney to ADH (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24094459'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; overall, hyponatremia risk is much higher within 2 to 4 weeks of initiating antidepressant therapy and the risk seems to diminish over time. By 3 to 6 months, the hyponatremia risk is the same as for patients who do not take antidepressants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28923523']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28923523'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25262043']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25262043'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25262043']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25262043'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Concomitant use of diuretics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25262043']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25262043'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Low body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25262043']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25262043'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i> Severe physical illness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25262043']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25262043'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Lower baseline serum sodium concentration (selective serotonin reuptake inhibitor [SSRI]–derived literature) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Volume depletion (potential risk factor; SSRI-derived literature) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> History of hyponatremia (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24094459'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Symptoms of psychosis (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24094459'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Specific antidepressant: TCAs have a lower risk for hyponatremia in comparison to SSRIs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25262043','lexi-content-ref-28923523']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25262043','lexi-content-ref-28923523'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ocular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Tricyclic antidepressants (TCAs) may cause <b>mydriasis </b>(pupillary dilation) and cycloplegia (affected eyes cannot focus on nearby objects), resulting in transient <b>accommodation disturbances</b> and <b>blurred vision</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4566251','lexi-content-ref-20443647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4566251','lexi-content-ref-20443647'])">Ref</a></span>). Mydriasis and cycloplegia usually improve over time as patients develop a tolerance to these effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20443647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20443647'])">Ref</a></span>). In susceptible individuals, TCA-induced mydriasis may result in the exacerbation of chronic angle-closure glaucoma and/or induction of acute angle-closure glaucoma (AACG). AACG may cause symptoms including eye pain, changes in vision, swelling, and redness, which can rapidly lead to permanent blindness if not treated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27993931']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27993931'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Mydriasis and cycloplegia are likely due to the anticholinergic effect of TCAs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4566251','lexi-content-ref-20443647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4566251','lexi-content-ref-20443647'])">Ref</a></span>). TCA-induced effects on norepinephrine and serotonin receptors in the iris and ciliary body of the eye, as well as alpha-adrenergic receptors may also play a role (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27993931','lexi-content-ref-20443647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27993931','lexi-content-ref-20443647'])">Ref</a></span>). In susceptible individuals, mydriasis can lead to AACG, which is caused by the physical obstruction of the outflow of intraocular fluid.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Blurred vision occurs in the initial stages of treatment with a TCA (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20443647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20443647'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">For AACG:</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>≥50 years of age (slight increase) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>Hyperopia (slight increase) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>Personal or family history of AACG (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>Inuit or Asian descent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>Narrow-angle glaucoma (avoid or use with extreme caution in these patients) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851','lexi-content-ref-20443647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851','lexi-content-ref-20443647'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>Specific tricyclic antidepressants: Nortriptyline is considered to display modest to moderate anticholinergic activity at typical doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18510583','lexi-content-ref-Riedel.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18510583','lexi-content-ref-Riedel.1'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Orthostatic hypotension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Tricyclic antidepressants (TCAs), including nortriptyline, may cause <b>orthostatic hypotension</b>, which may lead to syncope and subsequent falls, particularly in older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.1','lexi-content-ref-16961166','lexi-content-ref-21332244','lexi-content-ref-3323263','lexi-content-ref-3993532','lexi-content-ref-2521060']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.1','lexi-content-ref-16961166','lexi-content-ref-21332244','lexi-content-ref-3323263','lexi-content-ref-3993532','lexi-content-ref-2521060'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Alpha-adrenergic receptor blockade may lower systemic vascular resistance and result in hypotension, including orthostatic hypotension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21332244','lexi-content-ref-22936860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21332244','lexi-content-ref-22936860'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> In a small study of older adults ≥55 years of age treated with nortriptyline (mean dose: 79 mg/day), orthostatic hypotension appeared during the first week and generally persisted throughout the 7-week study period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3323263']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3323263'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Cardiovascular disease</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Hypovolemia/dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Concurrent medication use that may predispose to hypotension/bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Older adults, especially in those with preexisting heart conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.1','lexi-content-ref-29937420','lexi-content-ref-8444830']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.1','lexi-content-ref-29937420','lexi-content-ref-8444830'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>Specific TCA: Nortriptyline is associated with a lower risk of significant orthostatic hypotension compared to other TCAs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8444830','lexi-content-ref-6277997']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8444830','lexi-content-ref-6277997'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Serotonin syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Serotonin syndrome</b> has been reported and typically occurs with coadministration of multiple drugs with serotonin activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11127542']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11127542'])">Ref</a></span>). The diagnosis of serotonin syndrome is made based on the Hunter Serotonin Toxicity Criteria (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12925718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12925718'])">Ref</a></span>) and may result in a spectrum of symptoms, such as anxiety, agitation, confusion, delirium, hyperreflexia, muscle rigidity, myoclonus, tachycardia, tachypnea, hypertension, mydriasis, diaphoresis, and tremor. Severe cases may cause hyperthermia, significant autonomic instability (ie, rapid and severe changes in blood pressure and pulse), coma, and seizures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28148614','lexi-content-ref-15784664','lexi-content-ref-18759711']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28148614','lexi-content-ref-15784664','lexi-content-ref-18759711'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; overstimulation of serotonin receptors by serotonergic agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28148614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28148614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; in the majority of cases (74%), onset occurred within 24 hours of treatment initiation, overdose, or change in dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10941349']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10941349'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of drugs that increase serotonin synthesis, block serotonin reuptake, and/or impair serotonin metabolism (eg, monoamine oxidase inhibitors [MAOIs]). Of note, concomitant use of some serotonergic agents, such as MAOIs, is contraindicated.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Suicidal thinking and behavior</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants have been associated with an increased risk of suicidal thinking and suicidal behavior in pediatric and young adult patients (18 to 24 years) in short-term studies, per product labeling. In adults &gt;24 years of age, short-term studies did not show an increased risk of suicidal thinking and behavior, and in older adults ≥65 years of age, a decreased risk was observed. Although data have yielded inconsistent results regarding the association of antidepressants and risk of suicide, particularly among adults, some evidence shows a trend of an elevated risk of suicidality in younger age groups with certain antidepressants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17485726','lexi-content-ref-22309973','lexi-content-ref-16520440','lexi-content-ref-23152227','lexi-content-ref-12668373','lexi-content-ref-18056231','lexi-content-ref-31318184','lexi-content-ref-19832967','lexi-content-ref-16934334']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17485726','lexi-content-ref-22309973','lexi-content-ref-16520440','lexi-content-ref-23152227','lexi-content-ref-12668373','lexi-content-ref-18056231','lexi-content-ref-31318184','lexi-content-ref-19832967','lexi-content-ref-16934334'])">Ref</a></span>). Additionally, an observational study suggested an association with decreased rate of antidepressant prescribing and an increase in suicide rates in children and adolescents after the labeling was updated with the warnings (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17728420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17728420'])">Ref</a></span>). Of note, the risk of a suicide attempt is inherent in major depression and may persist until remission occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not established; one of several postulated mechanisms is antidepressants may energize suicidal patients to act on impulses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19209119']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19209119'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; increased risk observed in short-term studies (ie, &lt;4 months) in pediatric and young adults; it is unknown whether this risk extends to long-term use (ie, &gt;4 months).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Depression (risk of suicide is associated with major depression and may persist until remission occurs)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Withdrawal syndrome </b>has been reported in children and adults, primarily following abrupt discontinuation of tricyclic antidepressants (TCAs). Common symptoms include somatic symptoms (eg, lethargy, headache, tremor, sweating, anorexia); affective symptoms (eg, irritability, anxiety, agitation, low mood); sleep disorders (insomnia, excessive dreaming); and gastrointestinal disturbances (eg, nausea/vomiting, abdominal pain, anorexia). Rarely, movement disorders, such as akathisia or parkinsonism, hypomania/mania, <b>psychosis</b>, and/or cardiac arrhythmias may also occur. Of note, sensory abnormalities (eg, shock-like sensations, numbness), which are commonly reported with selective serotonin reuptake inhibitor withdrawal, are rarely seen with TCA withdrawal. Withdrawal symptoms may also occur following gradual tapering (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7912078','lexi-content-ref-16683858','lexi-content-ref-3624507','lexi-content-ref-11347722','lexi-content-ref-6707238','lexi-content-ref-15014601','lexi-content-ref-16913164']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7912078','lexi-content-ref-16683858','lexi-content-ref-3624507','lexi-content-ref-11347722','lexi-content-ref-6707238','lexi-content-ref-15014601','lexi-content-ref-16913164'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Withdrawal; due to reduced availability of serotonin in the CNS with decreasing levels of the serotonergic agent. Other neurotransmission systems, including increased glutamine and dopamine, may also be affected, as well as the hypothalamic-pituitary-adrenal axis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30501420','lexi-content-ref-16913164']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30501420','lexi-content-ref-16913164'])">Ref</a></span>). TCA-associated withdrawal symptoms may also be related in part to an adaptive hypersensitivity of muscarinic cholinergic receptors called cholinergic rebound or cholinergic overdrive and to involve noradrenergic mechanisms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3624507','lexi-content-ref-15014601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3624507','lexi-content-ref-15014601'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Symptoms generally appear within a few days of stopping or reducing the dosage of the antidepressant. Onset &gt;1 week later is unusual (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11347722','lexi-content-ref-15014601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11347722','lexi-content-ref-15014601'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Abrupt discontinuation (rather than gradual dose reduction) of an antidepressant treatment that has lasted for &gt;3 weeks, particularly a drug with a half-life &lt;24 hours (eg, paroxetine, venlafaxine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.1','lexi-content-ref-25677972','lexi-content-ref-Hirsch.1','lexi-content-ref-15906018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.1','lexi-content-ref-25677972','lexi-content-ref-Hirsch.1','lexi-content-ref-15906018'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Prior history of antidepressant withdrawal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>High dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.1'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F202681"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Some reactions listed are based on reports for other agents in this same pharmacologic class and may not be specifically reported for nortriptyline.</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Gastrointestinal: Sublingual adenitis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, cardiac arrhythmia (Bardai 2013), cerebrovascular accident, edema, flushing, heart block, hypertension, hypotension, orthostatic hypotension (Chandra 2006), palpitations, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, diaphoresis (excessive), pruritus, skin photosensitivity, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido, galactorrhea not associated with childbirth, gynecomastia, increased libido, increased serum glucose, SIADH, weight gain, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps, anorexia, constipation, diarrhea, epigastric discomfort, melanoglossia, nausea, paralytic ileus, parotid gland enlargement, stomatitis, unpleasant taste, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Breast hypertrophy, impotence, nocturia, testicular swelling, urinary frequency, urinary hesitancy, urinary retention, urinary tract dilation</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, bone marrow depression, eosinophilia, petechia, purpuric disease, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal liver function, cholestatic jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Drug-induced hypersensitivity reaction (tricyclic class)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, anxiety, ataxia, confusion, delusion, disorientation, dizziness, drowsiness, drug fever, EEG pattern changes, exacerbation of depression, extrapyramidal reaction, fatigue, hallucination, headache, hypomania, insomnia, nightmares, numbness, panic, peripheral neuropathy, restlessness, seizure, tingling of extremities, tingling sensation, withdrawal syndrome (Geller 1987)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Accommodation disturbance, blurred vision, mydriasis</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Polyuria</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac conduction disorder (Brugada syndrome exacerbation) (Alampay 2014), prolonged QT interval on ECG (Funai 2014), sinus tachycardia (Wilens 2006), widened QRS complex on ECG (Bardai 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pityriasis rosea (pityriasis rosea-like drug eruption) (Bangash 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cognitive dysfunction (Hoff 1990, Knegtering 1994), psychomotor impairment (Khade 2010), psychosis (including exacerbation of and associated with withdrawal syndrome) (Patterson 1984), serotonin syndrome (Hinds 2000), suicidal ideation, suicidal tendencies</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Angle-closure glaucoma</p></div>
<div class="block coi drugH1Div" id="F202697"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to nortriptyline and similar chemical class dibenzazepines, or any component of the formulation; use in a patient during the acute recovery phase of myocardial infarction; use of monoamine oxidase (MAO) inhibitors (concurrently or within 14 days of discontinuing either nortriptyline or the MAO inhibitor); initiation of nortriptyline in a patient receiving linezolid or IV methylene blue.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F202678"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with a history of cardiovascular disease (including previous MI, stroke, tachycardia).</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus; a causal relationship of tricyclic antidepressants with poor glycemic control has not been established, although some evidence of association exists. In addition, depression may reduce adherence to diabetic therapies (APA 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">• GI motility: Use with caution in patients with decreased GI motility (eg, paralytic ileus) as anticholinergic effects may exacerbate underlying condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; clearance of TCAs is decreased. Due to the narrow therapeutic index, use lower initial and maintenance doses of TCAs. Use caution in patients with hepatic encephalopathy due to the risk of neurocognitive effects (Mullish 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• Mania/hypomania: May precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Combination therapy with an antidepressant and a mood stabilizer should also be avoided in acute mania or mixed episodes, as well as maintenance treatment in bipolar disorder due to the mood-destabilizing effects of antidepressants (CANMAT [Yatham 2018]; WFSBP [Grunze 2018]). Patients presenting with depressive symptoms should be screened for bipolar disorder. Nortriptyline is not FDA approved for the treatment of bipolar depression.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ophthalmic conditions: Use with caution in patients with certain ophthalmic conditions as anticholinergic effects may exacerbate underlying condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use with caution in patients with a history of seizures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Urinary retention (eg, benign prostatic hyperplasia): Use with caution in patients with urinary retention as anticholinergic effects may exacerbate underlying condition.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Surgery: Recommended by the manufacturer to discontinue prior to elective surgery; risks exist for drug interactions with anesthesia and for cardiac arrhythmias. However, definitive drug interactions have not been widely reported in the literature and continuation of tricyclic antidepressants is generally recommended as long as precautions are taken to reduce the significance of any adverse events that may occur. Norepinephrine should be considered the vasopressor of choice for TCA-related hypotension (Pass 2004). Therapy should not be abruptly discontinued in patients receiving high doses for prolonged periods.</p></div>
<div class="block foc drugH1Div" id="F202690"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pamelor: 10 mg, 25 mg [contains fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pamelor: 50 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pamelor: 75 mg [contains fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 25 mg, 50 mg, 75 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/5 mL (473 mL)</p></div>
<div class="block geq drugH1Div" id="F202674"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F202699"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Nortriptyline HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.73 - $0.74</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $1.47</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $2.77</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $4.22</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Pamelor Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $47.15</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $48.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $49.04</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $49.98</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Nortriptyline HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/5 mL (per mL): $0.48</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867730"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aventyl: 10 mg, 25 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 25 mg</p></div>
<div class="block admp drugH1Div" id="F52613452"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May administer without regards to food; in pediatric patients, the timing of doses dependent upon use; for nocturnal enuresis and neuropathic pain, doses administered at bedtime; for ADHD, daily doses may be administered once daily in the morning or some have divided doses twice daily with a morning dose and a dose at dinner. </p></div>
<div class="block sts drugH1Div" id="F202708"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F). Protect from light.</p></div>
<div class="block meg drugH1Div" id="F7874747"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FDrugs%2FDrugSafety%2Fucm088671.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn%2F9%2Bevs591MjKrfB30zg8bRl9rTZV0lP8Ig%2FOIz%2BXgBq%2Fg%3D%3D&amp;TOPIC_ID=12653" target="_blank">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088671.pdf</a>, must be dispensed with this medication.</p></div>
<div class="block usep drugH1Div" id="F53568074"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of depression (FDA approved in adolescents and adults); has also been used in the treatment of attention deficit hyperactivity disorder (ADHD), nocturnal enuresis, and neuropathic pain.</p></div>
<div class="block mst drugH1Div" id="F202760"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Aventyl HCl may be confused with Bentyl</p>
<p style="text-indent:-2em;margin-left:4em;">Nortriptyline may be confused with amitriptyline, desipramine, Norpramin</p>
<p style="text-indent:-2em;margin-left:4em;">Pamelor may be confused with Demerol, Tambocor [DSC]</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Nortriptyline is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its strong anticholinergic properties and potential for sedation and orthostatic hypotension. In addition, use TCAs with caution due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F202746"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP2D6 (major), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F202683"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Almotriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists: Tricyclic Antidepressants may enhance the vasopressor effect of Alpha-/Beta-Agonists.  Management: Avoid, if possible, the use of alpha-/beta-agonists in patients receiving tricyclic antidepressants. If combined, monitor for evidence of increased pressor effects and consider reductions in initial dosages of the alpha-/beta-agonist.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Agonists: Tricyclic Antidepressants may enhance the therapeutic effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the therapeutic effect of Alpha1-Agonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha2-Agonists: Tricyclic Antidepressants may diminish the antihypertensive effect of Alpha2-Agonists.  Management: Consider avoiding this combination. If used, monitor for decreased effects of the alpha2-agonist. Exercise great caution if discontinuing an alpha2-agonist in a patient receiving a TCA.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha2-Agonists (Ophthalmic): Tricyclic Antidepressants may diminish the therapeutic effect of Alpha2-Agonists (Ophthalmic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Altretamine: May enhance the orthostatic hypotensive effect of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Amisulpride (Oral). Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: Tricyclic Antidepressants may enhance the adverse/toxic effect of Amphetamines. Tricyclic Antidepressants may potentiate the cardiovascular effects of Amphetamines. Amphetamines may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased cardiovascular effects when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole Lauroxil. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asenapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Asenapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May increase the metabolism of Tricyclic Antidepressants. Management: Monitor for decreased efficacy of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. Tricyclic antidepressant dose adjustments are likely required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Benperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta2-Agonists: Tricyclic Antidepressants may enhance the adverse/toxic effect of Beta2-Agonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Brexpiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the adverse/toxic effect of Tricyclic Antidepressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of BuPROPion. BuPROPion may increase the serum concentration of Tricyclic Antidepressants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Tricyclic Antidepressants may enhance the tachycardic effect of Cannabinoid-Containing Products. Blood pressure raising effects and drowsiness may also be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May decrease the serum concentration of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Cariprazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproMAZINE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ChlorproMAZINE. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: Tricyclic Antidepressants may enhance the serotonergic effect of Citalopram. Tricyclic Antidepressants may increase the serum concentration of Citalopram. Citalopram may increase the serum concentration of Tricyclic Antidepressants.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased TCA and citalopram concentrations/effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clothiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Clothiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the adverse/toxic effect of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyclobenzaprine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Moderate): May increase the serum concentration of Nortriptyline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase the serum concentration of Nortriptyline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Do not use serotonergic agents (high risk) with dapoxetine or within 7 days of serotonergic agent discontinuation. Do not use dapoxetine within 14 days of monoamine oxidase inhibitor use. Dapoxetine labeling lists this combination as contraindicated.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Tricyclic Antidepressants may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate-Methylphenidate: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dextromethorphan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: Tricyclic Antidepressants may enhance the arrhythmogenic effect of Dronedarone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome. DULoxetine may increase the serum concentration of Tricyclic Antidepressants. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased TCA concentrations and effects if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eletriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Escitalopram: Tricyclic Antidepressants may enhance the serotonergic effect of Escitalopram. Escitalopram may increase the serum concentration of Tricyclic Antidepressants.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased TCA concentrations/effects if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenfluramine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">FLUoxetine: May enhance the serotonergic effect of Tricyclic Antidepressants. FLUoxetine may increase the serum concentration of Tricyclic Antidepressants. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased TCA concentrations/effects if these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flupentixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Flupentixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluPHENAZine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of FluPHENAZine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluvoxaMINE: May enhance the serotonergic effect of Tricyclic Antidepressants. FluvoxaMINE may increase the serum concentration of Tricyclic Antidepressants. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased TCA concentrations/effects if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: Tricyclic Antidepressants may diminish the therapeutic effect of Guanethidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Haloperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iloperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iobenguane Radiopharmaceutical Products: Tricyclic Antidepressants may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Landiolol: Tricyclic Antidepressants may enhance the hypotensive effect of Landiolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lasmiditan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: Tricyclic Antidepressants may diminish the therapeutic effect of Lofexidine.  Management: Consider avoiding this drug combination when possible. If concurrent administration is required, monitor blood pressure carefully at the beginning of the combined therapy and when either drug is stopped. Adjust the dosage accordingly.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorcaserin (Withdrawn From US Market): May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome. Lorcaserin (Withdrawn From US Market) may increase the serum concentration of Tricyclic Antidepressants. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased TCA concentrations and effects if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Loxapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lumateperone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lurasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metaxalone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylene Blue: Tricyclic Antidepressants may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Consider monitoring for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molindone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Molindone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors (Antidepressant): May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: Tricyclic Antidepressants may enhance the serotonergic effect of Nefazodone. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: Tricyclic Antidepressants may enhance the hypotensive effect of Nicorandil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: Tricyclic Antidepressants may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of major adverse cardiac events (MACE), hemorrhagic stroke, ischemic stroke, and heart failure may be increased. Tricyclic Antidepressants may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of OLANZapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxitriptan: Serotonergic Agents (High Risk) may enhance the serotonergic effect of Oxitriptan. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the adverse/toxic effect of Serotonergic Agents (High Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paliperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Paliperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PARoxetine: May enhance the serotonergic effect of Tricyclic Antidepressants. PARoxetine may increase the serum concentration of Tricyclic Antidepressants. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased TCA concentrations/effects if these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Periciazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Periciazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perphenazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Perphenazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pimozide. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pipamperone [INT]: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pipamperone [INT]. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: Tricyclic Antidepressants may diminish the therapeutic effect of Pitolisant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prochlorperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Prochlorperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Promazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of QUEtiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rasagiline: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Nortriptyline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifapentine: May decrease the serum concentration of Nortriptyline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of RisperiDONE. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Safinamide: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selegiline: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk, Miscellaneous): Tricyclic Antidepressants may enhance the serotonergic effect of Serotonergic Agents (High Risk, Miscellaneous). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Non-Opioid CNS Depressants: Tricyclic Antidepressants may enhance the CNS depressant effect of Serotonergic Non-Opioid CNS Depressants. Tricyclic Antidepressants may enhance the serotonergic effect of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and CNS depression when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Opioids (High Risk): Tricyclic Antidepressants may enhance the CNS depressant effect of Serotonergic Opioids (High Risk). Serotonergic Opioids (High Risk) may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.  Management: Consider alternatives to this drug combination. If combined, monitor for signs and symptoms of serotonin syndrome/serotonin toxicity and CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin 5-HT1D Receptor Agonists (Triptans): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sertindole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertraline: May enhance the serotonergic effect of Tricyclic Antidepressants. Sertraline may increase the serum concentration of Tricyclic Antidepressants. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased TCA concentrations/effects if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. St John's Wort may decrease the serum concentration of Serotonergic Agents (High Risk). Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sulpiride. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Syrian Rue: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thioridazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiothixene: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thiothixene. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: May enhance the arrhythmogenic effect of Tricyclic Antidepressants. Thyroid Products may enhance the stimulatory effect of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobacco (Smoked): May decrease the serum concentration of Nortriptyline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the anticholinergic effect of other Tricyclic Antidepressants. Tricyclic Antidepressants may enhance the CNS depressant effect of other Tricyclic Antidepressants. Tricyclic Antidepressants may enhance the serotonergic effect of other Tricyclic Antidepressants. This could result in serotonin syndrome. Management: Monitor closely for increased TCA adverse effects, including serotonin syndrome/serotonin toxicity, CNS depression, and anticholinergic effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trifluoperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Trifluoperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May increase the serum concentration of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vasopressin: Drugs Suspected of Causing SIADH may enhance the therapeutic effect of Vasopressin. Specifically, the pressor and antidiuretic effects of vasopressin may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vilazodone: Tricyclic Antidepressants may enhance the serotonergic effect of Vilazodone. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vortioxetine: Tricyclic Antidepressants may enhance the serotonergic effect of Vortioxetine. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ziprasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Ziprasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Zuclopenthixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F57650519"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Tricyclic antidepressants (TCAs) are not preferred for the treatment of depression; however, if a TCA is needed in a patient planning to become pregnant, nortriptyline is preferred (Larsen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Nortriptyline is effective for prevention of migraines. In general, preventive treatment for migraine in patients trying to become pregnant should be avoided. Options for patients planning a pregnancy should be considered as part of a shared decision-making process. Nonpharmacologic interventions should be considered initially. When needed, preventive treatment should be individualized considering the available safety data and needs of the patient should pregnancy occur. A gradual discontinuation of preventive medications is generally preferred when the decision is made to stop treatment prior to conception (ACOG 2022; AHS [Ailani 2021]).</p></div>
<div class="block pri drugH1Div" id="F9465719"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Nortriptyline and its metabolites cross the human placenta and can be detected in cord blood (Loughhead 2006; Schoretsanitis 2021).</p>
<p style="text-indent:0em;display:inline">Tricyclic antidepressants (TCAs) may be associated with irritability, jitteriness, and convulsions (rare) in the neonate (Yonkers 2009). Increased crying, constipation, problems with urinating, respiratory distress, and nausea may also occur in neonates exposed during pregnancy (ACOG 2022; Larsen 2015).</p>
<p style="text-indent:0em;">Due to pregnancy-induced physiologic changes, the clearance of nortriptyline may be altered; therapeutic drug monitoring of nortriptyline is recommended monthly during pregnancy to avoid toxicity (Deligiannidis 2014; Larsen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Untreated or inadequately treated psychiatric illness may lead to poor adherence with prenatal care and adverse pregnancy outcomes. Therapy with antidepressants during pregnancy should be individualized; treatment with antidepressant medication is recommended for pregnant patients with severe major depressive disorder (ACOG 2008; CANMAT [MacQueen 2016]). Patients treated for major depression and who are euthymic prior to pregnancy are more likely to experience a relapse when medication is discontinued (68%) compared to pregnant patients who continue taking antidepressant medications (26%) (Cohen 2006). In general, TCAs are not preferred for the treatment of depression; however, nortriptyline is preferred if treatment with a TCA is initiated for the first-time during pregnancy (CANMAT [MacQueen 2016]; Larsen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">In general, preventive treatment for migraine should be avoided during pregnancy. Options for pregnant patients should be considered as part of a shared decision-making process. Nonpharmacologic interventions should be considered initially. When needed, preventive treatment should be individualized considering the available safety data, the potential for adverse maternal and fetal events, and the needs of the patient (ACOG 2022; AHS [Ailani 2021]). Efficacy data of TCAs for migraine prevention in pregnancy are limited and use is not recommended (ACOG 2022). Nortriptyline may be used if other agents are ineffective or contraindicated, considering the risks and benefits of use (ACOG 2022; CHS [Pringsheim 2012]).</p>
<p style="text-indent:0em;margin-top:2em;">Patients exposed to antidepressants during pregnancy are encouraged to enroll in the National Pregnancy Registry for Antidepressants (NPRAD). Patients 18 to 45 years of age or their health care providers may contact the registry by calling 844-405-6185. Enrollment should be done as early in pregnancy as possible.</p></div>
<div class="block mopp drugH1Div" id="F53568063"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Heart rate, blood pressure, ECG, mental status, weight, liver enzymes, CBC with differential, serum drug concentrations. Monitor patient periodically for symptom resolution; monitor for worsening depression, suicidality, and associated behaviors (especially at the beginning of therapy or when doses are increased or decreased); signs/symptoms of serotonin syndrome.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>ADHD:</b> Evaluate patients for cardiac disease prior to initiation of therapy for ADHD with thorough medical history, family history, and physical exam; consider ECG; perform ECG and echocardiogram if findings suggest cardiac disease; promptly conduct cardiac evaluation in patients who develop chest pain, unexplained syncope, or any other symptom of cardiac disease during treatment.</p></div>
<div class="block rerp drugH1Div" id="F53567924"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Therapeutic: 50 to 150 ng/mL (SI: 190 to 570 nmol/L)</p></div>
<div class="block pha drugH1Div" id="F202677"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Traditionally believed to increase the synaptic concentration of serotonin and/or norepinephrine in the central nervous system by inhibition of their reuptake by the presynaptic neuronal membrane. Inhibits the activity of histamine, 5-hydroxytryptamine, and acetylcholine. It increases the pressor effect of norepinephrine but blocks the pressor response of phenethylamine. However, additional receptor effects have been found including desensitization of adenyl cyclase, down regulation of beta-adrenergic receptors, and down regulation of serotonin receptors.</p></div>
<div class="block phk drugH1Div" id="F202696"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Depression: Initial effects may be observed within 1 to 2 weeks of treatment, with continued improvements through 4 to 6 weeks (Papakostas 2006; Posternak 2005; Szegedi 2009).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Rapid (Alexanderson 1972)</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 21.1 to 31.1 L/kg (Alexanderson 1972)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Extensively bound to plasma proteins (Alexanderson 1972)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily hepatic; extensive first-pass effect (Rubin 1985)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 46% to 70% (Rubin 1985)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 14 to 51 hours (mean: 26 hours) (Dawling 1980)</p>
<p style="text-indent:-2em;margin-left:4em;">Elderly: 23.5 to 79 hours (mean 45 hours) (Dawling 1980)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: 4 to 9 hours (Alexanderson 1972)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (as metabolites and small amounts of unchanged drug) (Alexanderson 1972)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038709"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Ateben</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Avelin | Nortin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cloridrato de nortriptilina | Nortrip | Pamelor</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Nortriptyline</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Aventyl</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Norcapto | Vividyl</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Aventyl | Nortriptyline HCL | Pamelor</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo-nortriptyline</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo-nortriptyline</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Aventyl</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Aventyl</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aventyl</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34160823">
<a name="34160823"></a>Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. <i>Headache</i>. 2021;61(7):1021-1039. doi:10.1111/head.14153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/34160823/pubmed" id="34160823" target="_blank">34160823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25444490">
<a name="25444490"></a>Alampay MM, Haigney MC, Flanagan MC, Perito RM, Love KM, Grammer GG. Transcranial magnetic stimulation as an antidepressant alternative in a patient with Brugada syndrome and recurrent syncope. <i>Mayo Clin Proc</i>. 2014;89(11):1584-1587. doi:10.1016/j.mayocp.2014.08.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/25444490/pubmed" id="25444490" target="_blank">25444490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4655685">
<a name="4655685"></a>Alexanderson B. Pharmacokinetics of nortriptyline in man after single and multiple oral doses: the predictability of steady-state plasma concentrations from single-dose plasma-level data. <i>Eur J Clin Pharmacol.</i> 1972;4(2):82-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/4655685/pubmed" id="4655685" target="_blank">4655685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35576364">
<a name="35576364"></a>American College of Obstetricians and Gynecologists (ACOG). Headaches in pregnancy and postpartum: ACOG clinical practice guideline no. 3. <i>Obstet</i>
<i>Gynecol</i>. 2022;139(5):944-972. doi:10.1097/AOG.0000000000004766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/35576364/pubmed" id="35576364" target="_blank">35576364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378767">
<a name="18378767"></a>American College of Obstetricians and Gynecologists (ACOG). Use of psychiatric medications during pregnancy and lactation: ACOG clinical practice guideline no. 92. <i>Obstet Gynecol</i>. 2008;111(4):1001-1020. doi:10.1097/AOG.0b013e31816fd910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/18378767/pubmed" id="18378767" target="_blank">18378767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APS.1">
<a name="APS.1"></a>American Pain Society (APS). <i>Principles of Analgesic Use</i>. Seventh Edition. Glenview, IL: American Pain Society; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.1">
<a name="APA.1"></a>American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Published October 2010. Accessed May 11, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20124882">
<a name="20124882"></a>American Society of Anesthesiologists Task Force on Chronic Pain Management; American Society of Regional Anesthesia and Pain Medicine. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. <i>Anesthesiology</i>. 2010;112(4):810-833. doi:10.1097/ALN.0b013e3181c43103<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/20124882/pubmed" id="20124882" target="_blank">20124882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4566251">
<a name="4566251"></a>Asberg M, Germanis M. Ophthalmological effects of nortriptyline--relationship to plasma level. <i>Pharmacology</i>. 1972;7(5):349-356. doi:10.1159/000136309<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/4566251/pubmed" id="4566251" target="_blank">4566251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20402746">
<a name="20402746"></a>Attal N, Cruccu G, Baron R, et al; European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. <i>Eur J Neurol.</i> 2010;17(9):1113-1123; e67-e88.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/20402746/pubmed" id="20402746" target="_blank">20402746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23425522">
<a name="23425522"></a>Bardai A, Amin AS, Blom MT, et al. Sudden cardiac arrest associated with use of a non-cardiac drug that reduces cardiac excitability: evidence from bench, bedside, and community. <i>Eur Heart J</i>. 2013;34(20):1506-1516. doi:10.1093/eurheartj/eht054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/23425522/pubmed" id="23425522" target="_blank">23425522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32809014">
<a name="32809014"></a>Barohn RJ, Gajewski B, Pasnoor M, et al; Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS) Study Team. Patient assisted intervention for neuropathy: comparison of treatment in real life situations (PAIN-CONTRoLS): Bayesian adaptive comparative effectiveness randomized trial. <i>JAMA Neurol.</i> 2021;78(1):68-76. doi:10.1001/jamaneurol.2020.2590<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/32809014/pubmed" id="32809014" target="_blank">32809014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28148614">
<a name="28148614"></a>Bartlett D. Drug-induced serotonin syndrome. <i>Crit Care Nurse</i>. 2017;37(1):49-54. doi:10.4037/ccn2017169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/28148614/pubmed" id="28148614" target="_blank">28148614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23879318">
<a name="23879318"></a>Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller HJ; World Federation of Societies of Biological Psychiatry. Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. <i>World J Biol Psychiatry</i>. 2013;14(5):334-385. doi:10.3109/15622975.2013.804195<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/23879318/pubmed" id="23879318" target="_blank">23879318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25677972">
<a name="25677972"></a>Bauer M, Severus E, Köhler S, Whybrow PC, Angst J, Möller HJ; WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: maintenance treatment of major depressive disorder-update 2015. <i>World J Biol Psychiatry</i>. 2015;16(2):76-95. doi: 10.3109/15622975.2014.1001786.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/25677972/pubmed" id="25677972" target="_blank">25677972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12479080">
<a name="12479080"></a>Bauer M, Whybrow PC, Anst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. <i>World J Biol Psychiatry</i>. 2002;3(2):69-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/12479080/pubmed" id="12479080" target="_blank">12479080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20482606">
<a name="20482606"></a>Bendtsen L, Evers S, Linde M, Mitsikostas DD, Sandrini G, Schoenen J; EFNS. EFNS guideline on the treatment of tension-type headache - report of an EFNS task force. <i>Eur J Neurol</i>. 2010;17(11):1318-1325. doi:10.1111/j.1468-1331.2010.03070.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/20482606/pubmed" id="20482606" target="_blank">20482606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8795600">
<a name="8795600"></a>Bendtsen L, Jensen R, Olesen J. A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. <i>J Neurol Neurosurg Psychiatry</i>. 1996;61(3):285-290. doi:10.1136/jnnp.61.3.285<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/8795600/pubmed" id="8795600" target="_blank">8795600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Biringer.2009">
<a name="Biringer.2009"></a>Biringer E, Rongve A, Lund A. A review of modern antidepressants' effects on neurocognitive function. <i>Curr Psych Rev</i>. 2009;5(3):1-11.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18049300">
<a name="18049300"></a>Birmaher B, Brent D, Bernet W, et al; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(11):1503-1526. doi:10.1097/chi.0b013e318145ae1c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/18049300/pubmed" id="18049300" target="_blank">18049300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35963508">
<a name="35963508"></a>Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update. <i>Endocr Pract</i>. 2022;28(10):923-1049. doi:10.1016/j.eprac.2022.08.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/35963508/pubmed" id="35963508" target="_blank">35963508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15784664">
<a name="15784664"></a>Boyer EW, Shannon M. The serotonin syndrome. <i>N Engl J Med</i>. 2005;352(11):1112-1120. Erratum in: <i>N Engl J Med</i>. 2007;356(23):2437. Erratum in: <i>N Engl J Med</i>. 2009;361(17):1714. doi:10.1056/NEJMra041867<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/15784664/pubmed" id="15784664" target="_blank">15784664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21767283">
<a name="21767283"></a>Braak B, Klooker TK, Wouters MM, Lei A, van den Wijngaard RM, Boeckxstaens GE. Randomised clinical trial: the effects of amitriptyline on drinking capacity and symptoms in patients with functional dyspepsia, a double-blind placebo-controlled study. <i>Aliment Pharmacol Ther</i>. 2011;34(6):638-648. doi:10.1111/j.1365-2036.2011.04775.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/21767283/pubmed" id="21767283" target="_blank">21767283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29937420">
<a name="29937420"></a>Briggs R, Carey D, McNicholas T, et al. The association between antidepressant use and orthostatic hypotension in older people: a matched cohort study.<i> J Am Soc Hypertens</i>. 2018;12(8):597-604.e1. doi:10.1016/j.jash.2018.06.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/29937420/pubmed" id="29937420" target="_blank">29937420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30895388">
<a name="30895388"></a>Burch R. Antidepressants for preventive treatment of migraine. <i>Curr Treat Options Neurol</i>. 2019;21(4):18. doi:10.1007/s11940-019-0557-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/30895388/pubmed" id="30895388" target="_blank">30895388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16961166">
<a name="16961166"></a>Chandra K, Shafiq N, Pandhi P, Gupta S, Malhotra S. Gabapentin versus nortriptyline in post-herpetic neuralgia patients: a randomized, double-blind clinical trial—the GONIP Trial. <i>Int J Clin Pharmacol Ther</i>. 2006;44(8):358-363.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/16961166/pubmed" id="16961166" target="_blank">16961166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35738724">
<a name="35738724"></a>Chang L, Sultan S, Lembo A, Verne GN, Smalley W, Heidelbaugh JJ. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with constipation. <i>Gastroenterology</i>. 2022;163(1):118-136. doi:10.1053/j.gastro.2022.04.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/35738724/pubmed" id="35738724" target="_blank">35738724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18510583">
<a name="18510583"></a>Chew ML, Mulsant BH, Pollock BG, et al. Anticholinergic activity of 107 medications commonly used by older adults. <i>J Am Geriatr Soc</i>. 2008;56(7):1333-1341. doi:10.1111/j.1532-5415.2008.01737.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/18510583/pubmed" id="18510583" target="_blank">18510583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16449615">
<a name="16449615"></a>Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. <i>JAMA</i>. 2006;295(5):499-507. doi:10.1001/jama.295.5.499<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/16449615/pubmed" id="16449615" target="_blank">16449615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19587851">
<a name="19587851"></a>Costagliola C, Parmeggiani F, Semeraro F, Sebastiani A. Selective serotonin reuptake inhibitors: a review of its effects on intraocular pressure. <i>Curr Neuropharmacol</i>. 2008;6(4):293-310. doi:10.2174/157015908787386104<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/19587851/pubmed" id="19587851" target="_blank">19587851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6994983">
<a name="6994983"></a>Dawling S, Crome P, Braithwaite R. Pharmacokinetics of Single Oral Doses of Nortriptyline in Depressed Elderly Hospital Patients and Young Healthy Volunteers. <i>Clin Pharmacokinet.</i> 1980;5(4):394-401.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/6994983/pubmed" id="6994983" target="_blank">6994983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7105623">
<a name="7105623"></a>Dawling S, Lynn K, Rosser R, Braithwaite R. Nortriptyline metabolism in chronic renal failure: metabolite elimination. <i>Clin Pharmacol Ther.</i> 1982;32(3):322-329. doi:10.1038/clpt.1982.167<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/7105623/pubmed" id="7105623" target="_blank">7105623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7248140">
<a name="7248140"></a>Dawling S, Lynn K, Rosser R, Braithwaite R. The pharmacokinetics of nortriptyline in patients with chronic renal failure.<i> Br J Clin Pharmacol.</i> 1981;12(1):39-45. doi:10.1111/j.1365-2125.1981.tb01852.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/7248140/pubmed" id="7248140" target="_blank">7248140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24525634">
<a name="24525634"></a>Deligiannidis KM, Byatt N, Freeman MP. Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring.<i> J Clin Psychopharmacol</i>. 2014;34(2):244-255. doi:10.1097/JCP.0000000000000087<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/24525634/pubmed" id="24525634" target="_blank">24525634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25262043">
<a name="25262043"></a>De Picker L, Van Den Eede F, Dumont G, et al. Antidepressants and the risk of hyponatremia: a class-by-class review of literature. <i>Psychosomatics</i>. 2014;55(6):536-547. doi: 10.1016/j.psym.2014.01.010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/25262043/pubmed" id="25262043" target="_blank">25262043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25135034">
<a name="25135034"></a>Desai MJ, Saini V, Saini S. Myofascial pain syndrome: a treatment review. <i>Pain Ther</i>. 2013;2(1):21-36. doi:10.1007/s40122-013-0006-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/25135034/pubmed" id="25135034" target="_blank">25135034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22168597">
<a name="22168597"></a>Deshpande AV, Caldwell PH. Medical management of nocturnal enuresis. <i>Paediatr Drugs</i>. 2012;14(2):71-77. doi:10.2165/11594870-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/22168597/pubmed" id="22168597" target="_blank">22168597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21332244">
<a name="21332244"></a>Dhippayom T, Chaiyakunapruk N, Jongchansittho T. Safety of nortriptyline at equivalent therapeutic doses for smoking cessation: a systematic review and meta-analysis. <i>Drug Saf</i>. 2011;34(3):199-210. doi:10.2165/11585950-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/21332244/pubmed" id="21332244" target="_blank">21332244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7912078">
<a name="7912078"></a>Dilsaver SC. Withdrawal phenomena associated with antidepressant and antipsychotic agents. <i>Drug Saf</i>. 1994;10(2):103-114. doi:10.2165/00002018-199410020-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/7912078/pubmed" id="7912078" target="_blank">7912078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15998933">
<a name="15998933"></a>Dopheide JA. ASHP therapeutic position statement on the appropriate use of medications in the treatment of attention-deficit/hyperactivity disorder in pediatric patients. <i>Am J Health Syst Pharm</i>. 2005;62(14):1502-1509.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/15998933/pubmed" id="15998933" target="_blank">15998933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16434782">
<a name="16434782"></a>Dopheide JA. Recognizing and Treating Depression in Children and Adolescents. <i>Am J Health Syst Pharm.</i> 2006;63(3):233-243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/16434782/pubmed" id="16434782" target="_blank">16434782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12925718">
<a name="12925718"></a>Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. <i>QJM</i>. 2003;96(9):635-642. doi:10.1093/qjmed/hcg109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/12925718/pubmed" id="12925718" target="_blank">12925718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36507636">
<a name="36507636"></a>ElSayed NA, Aleppo G, Aroda VR, et al; American Diabetes Association. 12. Retinopathy, neuropathy, and foot care: standards of care in diabetes-2023. <i>Diabetes Care</i>. 2023;46(suppl 1):S203-S215. doi:10.2337/dc23-S012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/36507636/pubmed" id="36507636" target="_blank">36507636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25857865">
<a name="25857865"></a>Eyler RF, Unruh ML, Quinn DK, Vilay AM. Psychotherapeutic agents in end-stage renal disease. <i>Semin Dial.</i> 2015;28(4):417-426. doi:10.1111/sdi.12370<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/25857865/pubmed" id="25857865" target="_blank">25857865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16683858">
<a name="16683858"></a>Fava M. Prospective studies of adverse events related to antidepressant discontinuation. <i>J Clin Psychiatry</i>. 2006;67(Suppl 4):14-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/16683858/pubmed" id="16683858" target="_blank">16683858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Feldman.1">
<a name="Feldman.1"></a>Feldman EL. Management of diabetic neuropathy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 22, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19621834">
<a name="19621834"></a>Fenske JN, Schwenk TL. Obsessive compulsive disorder: diagnosis and management. <i>Am Fam Physician</i>. 2009;80(3):239-245.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/19621834/pubmed" id="19621834" target="_blank">19621834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25575710">
<a name="25575710"></a>Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. <i>Lancet Neurol.</i> 2015;14(2):162-173. doi:10.1016/S1474-4422(14)70251-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/25575710/pubmed" id="25575710" target="_blank">25575710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36791365">
<a name="36791365"></a>Frazier R, Li BUK, Venkatesan T. Diagnosis and management of cyclic vomiting syndrome: a critical review. <i>Am J Gastroenterol</i>. 2023;118(7):1157-1167. doi:10.14309/ajg.0000000000002216<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/36791365/pubmed" id="36791365" target="_blank">36791365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17485726">
<a name="17485726"></a>Friedman RA, Leon AC. Expanding the black box - depression, antidepressants, and the risk of suicide. <i>N Engl J Med</i>. 2007;356(23):2343-2346. doi:10.1056/NEJMp078015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/17485726/pubmed" id="17485726" target="_blank">17485726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25272563">
<a name="25272563"></a>Funai Y, Funao T, Ikenaga K, Takahashi R, Hase I, Nishikawa K. Use of tricyclic antidepressants as analgesic adjuvants results in nonhazardous prolongation of the QTc interval. <i>Osaka City Med J</i>. 2014;60(1):11-19.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/25272563/pubmed" id="25272563" target="_blank">25272563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gal.2007">
<a name="Gal.2007"></a>Gal P, Reed M. Medications. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007: 2955-2999.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12544371">
<a name="12544371"></a>Gastó C, Navarro V, Marcos T, Portella MJ, Torra M, Rodamilans M. Single-blind comparison of venlafaxine and nortriptyline in elderly major depression.<i> J Clin Psychopharmacol.</i> 2003;23(1):21-26. doi:10.1097/00004714-200302000-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/12544371/pubmed" id="12544371" target="_blank">12544371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3624507">
<a name="3624507"></a>Geller B, Cooper TB, Carr LG, Warham JE, Rodriguez A. Prospective study of scheduled withdrawal from nortriptyline in children and adolescents. <i>J Clin Psychopharmacol</i>. 1987;7(4):252-254.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/3624507/pubmed" id="3624507" target="_blank">3624507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3323263">
<a name="3323263"></a>Georgotas A, McCue RE, Friedman E, Cooper TB. A placebo-controlled comparison of the effect of nortriptyline and phenelzine on orthostatic hypotension in elderly depressed patients. <i>J Clin Psychopharmacol</i>. 1987;7(6):413-416.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/3323263/pubmed" id="3323263" target="_blank">3323263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3993532">
<a name="3993532"></a>Giardina EG, Johnson LL, Vita J, Bigger JT Jr, Brem RF. Effect of imipramine and nortriptyline on left ventricular function and blood pressure in patients treated for arrhythmias. <i>Am Heart J</i>. 1985;109(5 pt 1):992-998. doi:10.1016/0002-8703(85)90240-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/3993532/pubmed" id="3993532" target="_blank">3993532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17728420">
<a name="17728420"></a>Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. <i>Am J Psychiatry</i>. 2007;164(9):1356-1363. doi:10.1176/appi.ajp.2007.07030454<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/17728420/pubmed" id="17728420" target="_blank">17728420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22309973">
<a name="22309973"></a>Gibbons RD, Brown CH, Hur K, Davis J, Mann JJ. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. <i>Arch Gen Psychiatry</i>. 2012;69(6):580-587. Erratum in: <i>Arch Gen Psychiatry</i>. 2013 Aug;70(8):881. doi:10.1001/archgenpsychiatry.2011.2048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/22309973/pubmed" id="22309973" target="_blank">22309973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19796802">
<a name="19796802"></a>Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. <i>Lancet</i>. 2009;374(9697):1252-1261.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/19796802/pubmed" id="19796802" target="_blank">19796802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14645327">
<a name="14645327"></a>Gjerdingen D. The effectiveness of various postpartum depression treatments and the impact of antidepressant drugs on nursing infants. <i>J Am Board Fam Pract</i>. 2003;16(5):372-382.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/14645327/pubmed" id="14645327" target="_blank">14645327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8444830">
<a name="8444830"></a>Glassman AH, Preud'homme XA. Review of the cardiovascular effects of heterocyclic antidepressants. <i>J Clin Psychiatry</i>. 1993;54 Suppl:16-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/8444830/pubmed" id="8444830" target="_blank">8444830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15509460">
<a name="15509460"></a>Graff-Radford SB. Myofascial pain: diagnosis and management. <i>Curr Pain Headache Rep</i>. 2004;8(6):463-467. doi:10.1007/s11916-004-0068-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/15509460/pubmed" id="15509460" target="_blank">15509460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29098925">
<a name="29098925"></a>Grunze H, Vieta E, Goodwin GM, et al; Members of the WFSBP Task Force on Bipolar Affective Disorders working on this topic. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Acute and long-term treatment of mixed states in bipolar disorder. <i>World J Biol Psychiatry</i>. 2018;19(1):2-58. doi: 10.1080/15622975.2017.1384850.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/29098925/pubmed" id="29098925" target="_blank">29098925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11347722">
<a name="11347722"></a>Haddad PM. Antidepressant discontinuation syndromes. <i>Drug Saf</i>. 2001;24(3):183-197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/11347722/pubmed" id="11347722" target="_blank">11347722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15514412">
<a name="15514412"></a>Hall SM, Humfleet GL, Reus VI, Muñoz RF, Cullen J. Extended nortriptyline and psychological treatment for cigarette smoking. <i>Am J Psychiatry</i>. 2004;161(11):2100-2107. doi:10.1176/appi.ajp.161.11.2100<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/15514412/pubmed" id="15514412" target="_blank">15514412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12365880">
<a name="12365880"></a>Hall SM, Humfleet GL, Reus VI, Muñoz RF, Hartz DT, Maude-Griffin R. Psychological intervention and antidepressant treatment in smoking cessation. <i>Arch Gen Psychiatry</i>. 2002;59(10):930-936. doi:10.1001/archpsyc.59.10.930<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/12365880/pubmed" id="12365880" target="_blank">12365880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9707377">
<a name="9707377"></a>Hall SM, Reus VI, Muñoz RF, et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. <i>Arch Gen Psychiatry.</i> 1998;55(8):683-690. doi:10.1001/archpsyc.55.8.683<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/9707377/pubmed" id="9707377" target="_blank">9707377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16520440">
<a name="16520440"></a>Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. <i>Arch Gen Psychiatry</i>. 2006;63(3):332-339. doi:10.1001/archpsyc.63.3.332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/16520440/pubmed" id="16520440" target="_blank">16520440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29337001">
<a name="29337001"></a>Hathaway EE, Walkup JT, Strawn JR. Antidepressant Treatment Duration in Pediatric Depressive and Anxiety Disorders: How Long is Long Enough? <i>Curr Probl Pediatr Adolesc Health Care</i>. 2018;48(2):31-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/29337001/pubmed" id="29337001" target="_blank">29337001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25905532">
<a name="25905532"></a>Haviv Y, Rettman A, Aframian D, Sharav Y, Benoliel R. Myofascial pain: an open study on the pharmacotherapeutic response to stepped treatment with tricyclic antidepressants and gabapentin. <i>J Oral Facial Pain Headache</i>. 2015;29(2):144-151. doi:10.11607/ofph.1408<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/25905532/pubmed" id="25905532" target="_blank">25905532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20027010">
<a name="20027010"></a>Hejazi RA, Reddymasu SC, Namin F, Lavenbarg T, Foran P, McCallum RW. Efficacy of tricyclic antidepressant therapy in adults with cyclic vomiting syndrome: a two-year follow-up study. <i>J Clin Gastroenterol.</i> 2010;44(1):18-21. doi:10.1097/MCG.0b013e3181ac6489<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/20027010/pubmed" id="20027010" target="_blank">20027010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23152227">
<a name="23152227"></a>Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. <i>Cochrane Database Syst Rev</i>. 2012;11:CD004851. doi:10.1002/14651858.CD004851.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/23152227/pubmed" id="23152227" target="_blank">23152227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28910830">
<a name="28910830"></a>Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. <i>Pharmacopsychiatry</i>. 2018;51(1-02):9-62. doi: 10.1055/s-0043-116492.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/28910830/pubmed" id="28910830" target="_blank">28910830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11127542">
<a name="11127542"></a>Hinds NP, Hillier CE, Wiles CM. Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. <i>J Neurol</i>. 2000;247(10):811. doi:10.1007/s004150070101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/11127542/pubmed" id="11127542" target="_blank">11127542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.1">
<a name="Hirsch.1"></a>Hirsch M, Birnbaum RJ. Discontinuing antidepressant medications in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 11, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.2">
<a name="Hirsch.2"></a>Hirsch M, Birnbaum RJ. Switching antidepressant medications in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 30, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.3">
<a name="Hirsch.3"></a>Hirsch M, Birnbaum RJ. Tricyclic and tetracyclic drugs: pharmacology, administration and side effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 22, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2376622">
<a name="2376622"></a>Hoff AL, Shukla S, Helms P, et al. The effects of nortriptyline on cognition in elderly depressed patients. <i>J Clin Psychopharmacol</i>. 1990;10(3):231-232. doi:10.1097/00004714-199006000-00025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/2376622/pubmed" id="2376622" target="_blank">2376622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11325322">
<a name="11325322"></a>Holroyd KA, O'Donnell FJ, Stensland M, Lipchik GL, Cordingley GE, Carlson BW. Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy, and their combination: a randomized controlled trial. <i>JAMA</i>. 2001;285(17):2208-2215. doi:10.1001/jama.285.17.2208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/11325322/pubmed" id="11325322" target="_blank">11325322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12835289">
<a name="12835289"></a>Hubbard R, Farrington P, Smith C, Smeeth L, Tattersfield A. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. <i>Am J Epidemiol</i>. 2003;158(1):77-84. doi:10.1093/aje/kwg114<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/12835289/pubmed" id="12835289" target="_blank">12835289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Isaac.1">
<a name="Isaac.1"></a>Isaac Z. Management of non-radicular neck pain in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 22, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16896026">
<a name="16896026"></a>Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. <i>Ann Pharmacother</i>. 2006;40(9):1618-1622. doi:10.1345/aph.1G293<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/16896026/pubmed" id="16896026" target="_blank">16896026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30501420">
<a name="30501420"></a>Jha MK, Rush AJ, Trivedi MH. When discontinuing SSRI antidepressants Is a challenge: Management tips. <i>Am J Psychiatry</i>. 2018;175(12):1176-1184. doi:10.1176/appi.ajp.2018.18060692<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/30501420/pubmed" id="30501420" target="_blank">30501420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spadt.1">
<a name="Spadt.1"></a>Kellogg Spadt S, Kingsberg S. Vulvar pain of unknown cause (vulvodynia): treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 30, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21716778">
<a name="21716778"></a>Khade A, Bashir MS, Kale AS, Turankar A. Study of the effect of nortriptyline and fluvoxamine on psychomotor functions in healthy volunteers. <i>Indian J Psychol Med</i>. 2010;32(2):104-107. doi:10.4103/0253-7176.78506<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/21716778/pubmed" id="21716778" target="_blank">21716778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12668373">
<a name="12668373"></a>Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. <i>Am J Psychiatry</i>. 2003;160(4):790-792. doi:10.1176/appi.ajp.160.4.790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/12668373/pubmed" id="12668373" target="_blank">12668373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17182183">
<a name="17182183"></a>Khoromi S, Cui L, Nackers L, Max MB. Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. <i>Pain</i>. 2007;130(1-2):66-75. doi:10.1016/j.pain.2006.10.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/17182183/pubmed" id="17182183" target="_blank">17182183</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27993931">
<a name="27993931"></a>Kirkham J, Seitz D. Evidence of ocular side effects of SSRIs and new warnings. <i>Evid Based Ment Health</i>. 2017;20(1):27. doi:10.1136/eb-2016-102528<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/27993931/pubmed" id="27993931" target="_blank">27993931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/Kliegman.1/pubmed" id="Kliegman.1" target="_blank">Kliegman.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7803947">
<a name="7803947"></a>Knegtering H, Eijck M, Huijsman A. Effects of antidepressants on cognitive functioning of elderly patients. A review. <i>Drugs Aging</i>. 1994;5(3):192-199. doi:10.2165/00002512-199405030-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/7803947/pubmed" id="7803947" target="_blank">7803947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17562523">
<a name="17562523"></a>Kok RM, Nolen WA, Heeren TJ. Venlafaxine versus nortriptyline in the treatment of elderly depressed inpatients: a randomised, double-blind, controlled trial. <i>Int J Geriatr Psychiatry</i>. 2007;22(12):1247-1254. doi:10.1002/gps.1823<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/17562523/pubmed" id="17562523" target="_blank">17562523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33315591">
<a name="33315591"></a>Lacy BE, Pimentel M, Brenner DM, et al. ACG clinical guideline: management of irritable bowel syndrome. <i>Am J Gastroenterol</i>. 2021;116(1):17-44. doi:10.14309/ajg.0000000000001036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/33315591/pubmed" id="33315591" target="_blank">33315591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19661763">
<a name="19661763"></a>Lanza di Scalea T, Wisner KL. Antidepressant medication use during breastfeeding. <i>Clin Obstet Gynecol</i>. 2009;52(3):483-497.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/19661763/pubmed" id="19661763" target="_blank">19661763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35738725">
<a name="35738725"></a>Lembo A, Sultan S, Chang L, Heidelbaugh JJ, Smalley W, Verne GN. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea. <i>Gastroenterology</i>. 2022;163(1):137-151. doi:10.1053/j.gastro.2022.04.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/35738725/pubmed" id="35738725" target="_blank">35738725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18056231">
<a name="18056231"></a>Leon AC. The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses. <i>Am J Psychiatry</i>. 2007;164(12):1786-1789. doi:10.1176/appi.ajp.2007.07050775<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/18056231/pubmed" id="18056231" target="_blank">18056231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Li.1">
<a name="Li.1"></a>Li B UK. Cyclic vomiting syndrome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 22, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3971655">
<a name="3971655"></a>Lieberman JA, Cooper TB, Suckow RF, et al. Tricyclic antidepressant and metabolite levels in chronic renal failure.<i> Clin Pharmacol Ther.</i> 1985;37(3):301-307. doi:10.1038/clpt.1985.44<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/3971655/pubmed" id="3971655" target="_blank">3971655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28923523">
<a name="28923523"></a>Lien YH. Antidepressants and Hyponatremia. <i>Am J Med</i>. 2018;131(1):7-8. doi:10.1016/j.amjmed.2017.09.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/28923523/pubmed" id="28923523" target="_blank">28923523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23937282">
<a name="23937282"></a>Liu WQ, Kanungo A, Toth C. Equivalency of tricyclic antidepressants in open-label neuropathic pain study. <i>Acta Neurol Scand</i>. 2014;129(2):132-141. doi:10.1111/ane.12169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/23937282/pubmed" id="23937282" target="_blank">23937282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Longstreth.1">
<a name="Longstreth.1"></a>Longstreth GF, Lacy BE. Functional dyspepsia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 19, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16271264">
<a name="16271264"></a>Loughhead AM, Stowe ZN, Newport DJ, et al. Placental Passage of Tricyclic Antidepressants. <i>Biol Psychiatry.</i> 2006;59(3):287-290.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/16271264/pubmed" id="16271264" target="_blank">16271264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27486149">
<a name="27486149"></a>MacQueen GM, Frey BN, Ismail Z, et al; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 6. Special populations: youth, women, and the elderly. <i>Can J Psychiatry</i>. 2016;61(9):588-603. doi:10.1177/0706743716659276<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/27486149/pubmed" id="27486149" target="_blank">27486149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31318184">
<a name="31318184"></a>Madsen T, Buttenschøn HN, Uher R, et al. Trajectories of suicidal ideation during 12 weeks of escitalopram or nortriptyline antidepressant treatment among 811 patients with major depressive disorder. <i>J Clin Psychiatry</i>. 2019;80(4):18m12575. doi:10.4088/JCP.18m12575<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/31318184/pubmed" id="31318184" target="_blank">31318184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24094459">
<a name="24094459"></a>Mannesse CK, Jansen PA, Van Marum RJ, et al. Characteristics, prevalence, risk factors, and underlying mechanism of hyponatremia in elderly patients treated with antidepressants: a cross-sectional study. <i>Maturitas</i>. 2013;76(4):357-363. doi:10.1016/j.maturitas.2013.08.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/24094459/pubmed" id="24094459" target="_blank">24094459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10607968">
<a name="10607968"></a>Marraccini RL, Reynolds CF 3rd, Houck PR, et al. A double-blind, placebo-controlled assessment of nortriptyline's side-effects during 3-year maintenance treatment in elderly patients with recurrent major depression. <i>Int J Geriatr Psychiatry</i>. 1999;14(12):1014-1018.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/10607968/pubmed" id="10607968" target="_blank">10607968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10941349">
<a name="10941349"></a>Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. <i>Medicine (Baltimore)</i>. 2000;79(4):201-209. doi:10.1097/00005792-200007000-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/10941349/pubmed" id="10941349" target="_blank">10941349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3191943">
<a name="3191943"></a>Matheson I, Skjaeraasen J. Milk concentrations of flupenthixol, nortriptyline and zuclopenthixol and between-breast differences in two patients. <i>Eur J Clin Pharmacol.</i> 1988;35(2):217-220.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/3191943/pubmed" id="3191943" target="_blank">3191943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25248846">
<a name="25248846"></a>Mauri MC, Fiorentini A, Paletta S, Altamura AC. Pharmacokinetics of antidepressants in patients with hepatic impairment. <i>Clin Pharmacokinet</i>. 2014;53(12):1069-1081. doi:10.1007/s40262-014-0187-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/25248846/pubmed" id="25248846" target="_blank">25248846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2521060">
<a name="2521060"></a>McCue RE, Georgotas A, Suckow RF, Cooper TB. 10-Hydroxynortriptyline and treatment effects in elderly depressed patients. <i>J Neuropsychiatry Clin Neurosci</i>. 1989;1(2):176-180. doi:10.1176/jnp.1.2.176<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/2521060/pubmed" id="2521060" target="_blank">2521060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mehta.1">
<a name="Mehta.1"></a>Mehta NR, Keith DK. Temporomandibular disorders in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 22, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28631728">
<a name="28631728"></a>Moayyedi P, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline: management of dyspepsia. <i>Am J Gastroenterol.</i> 2017;112(7):988-1013. doi:10.1038/ajg.2017.154<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/28631728/pubmed" id="28631728" target="_blank">28631728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17372630">
<a name="17372630"></a>Moulin DE, Clark AJ, Gilron I, et al; Canadian Pain Society. Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. <i>Pain Res Manag</i>. 2007;12(1):13-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/17372630/pubmed" id="17372630" target="_blank">17372630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25175904">
<a name="25175904"></a>Mullish BH, Kabir MS, Thursz MR, Dhar A. Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation. <i>Aliment Pharmacol Ther</i>. 2014;40(8):880-892. doi:10.1111/apt.12925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/25175904/pubmed" id="25175904" target="_blank">25175904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22859791">
<a name="22859791"></a>Nagler EV, Webster AC, Vanholder R, Zoccali C. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). <i>Nephrol Dial Transplant</i>. 2012;27(10):3736-3745. doi:10.1093/ndt/gfs295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/22859791/pubmed" id="22859791" target="_blank">22859791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22132433">
<a name="22132433"></a>National Collaborating Centre for Mental Health (NCCMH). Depression: The Treatment and Management of Depression in Adults (Updated Edition). National Institute for Health &amp; Clinical Excellence (NICE). 2010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/22132433/pubmed" id="22132433" target="_blank">22132433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Collaborating Centre for Nursing and Supportive Care; National Institute for Health and Clinical Excellence. Clinical practice guideline: irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care. https://www.nice.org.uk/guidance/cg61/evidence/full-guidance-196701661. Published February 2008. Updated March 2017. Accessed June 3, 2021.</div>
</li>
<li>
<div class="reference">
                  Nortriptyline [prescribing information]. North Wales, PA: Teva Pharmaceuticals Inc.; May 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NortriptylineHCl.1">
<a name="NortriptylineHCl.1"></a>Nortriptyline hydrochloride oral solution, USP [prescribing information]. Greenville, SC: Pharmaceutical Associates Inc; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23459282">
<a name="23459282"></a>Ogle NR, Akkerman SR. Guidance for the discontinuation or switching of antidepressant therapies in adults. <i>J Pharm Pract</i>. 2013;26(4):389-396. doi:10.1177/0897190012467210<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/23459282/pubmed" id="23459282" target="_blank">23459282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ortega.1">
<a name="Ortega.1"></a>Ortega E. Postherpetic neuralgia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 22, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15320756">
<a name="15320756"></a>Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? <i>Curr Pharm Des</i>. 2004;10(20):2463-2475. doi:10.2174/1381612043383872<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/15320756/pubmed" id="15320756" target="_blank">15320756</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Pamelor (nortriptyline) capsules [prescribing information]. Hazelwood, MO: Mallinckrodt Inc; April 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16415707">
<a name="16415707"></a>Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. <i>J Clin Psychopharmacol</i>. 2006;26(1):56-60. doi:10.1097/01.jcp.0000195042.62724.76<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/16415707/pubmed" id="16415707" target="_blank">16415707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15156966">
<a name="15156966"></a>Pass SE, Simpson RW. Discontinuation and Reinstitution of Medications During the Perioperative Period. <i>Am J Health Syst Pharm.</i> 2004;61(9):899-912.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/15156966/pubmed" id="15156966" target="_blank">15156966</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6707238">
<a name="6707238"></a>Patterson JF. Psychosis after discontinuation of nortriptyline. <i>J Clin Psychopharmacol</i>. 1984;4(2):117-118.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/6707238/pubmed" id="6707238" target="_blank">6707238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19832967">
<a name="19832967"></a>Perroud N, Uher R, Marusic A, et al. Suicidal ideation during treatment of depression with escitalopram and nortriptyline in genome-based therapeutic drugs for depression (GENDEP): a clinical trial. <i>BMC Med</i>. 2009;7:60. doi:10.1186/1741-7015-7-60<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/19832967/pubmed" id="19832967" target="_blank">19832967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9586488">
<a name="9586488"></a>Pettengill CA, Reisner-Keller L. The use of tricyclic antidepressants for the control of chronic orofacial pain. <i>Cranio</i>. 1997;15(1):53-56. doi:10.1080/08869634.1997.11745992<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/9586488/pubmed" id="9586488" target="_blank">9586488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17581453">
<a name="17581453"></a>Pliszka S and AACAP Work Group on Quality Issues. Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. <i>J Am Acad Child Adolesc Psychiatry.</i> 2007;46(7):894-921.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/17581453/pubmed" id="17581453" target="_blank">17581453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9699704">
<a name="9699704"></a>Pollock BG, Mulsant BH, Nebes R, et al. Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline. <i>Am J Psychiatry</i>. 1998;155(8):1110-1112. doi:10.1176/ajp.155.8.1110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/9699704/pubmed" id="9699704" target="_blank">9699704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27999003">
<a name="27999003"></a>Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: A position statement by the American Diabetes Association. <i>Diabetes Care</i>. 2017;40(1):136-154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/27999003/pubmed" id="27999003" target="_blank">27999003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15704999">
<a name="15704999"></a>Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. <i>J Clin Psychiatry</i>. 2005;66(2):148-158. doi:10.4088/jcp.v66n0201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/15704999/pubmed" id="15704999" target="_blank">15704999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2140373">
<a name="2140373"></a>Preskorn SH, Jerkovich GS. Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors, and role of therapeutic drug monitoring. <i>J Clin Psychopharmacol</i>. 1990;10(2):88-95. doi:10.1097/00004714-199004000-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/2140373/pubmed" id="2140373" target="_blank">2140373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34965987">
<a name="34965987"></a>Price R, Smith D, Franklin G, et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: report of the AAN Guideline Subcommittee. <i>Neurology</i>. 2022;98(1):31-43. doi:10.1212/WNL.0000000000013038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/34965987/pubmed" id="34965987" target="_blank">34965987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11052409">
<a name="11052409"></a>Prince JB, Wilens TE, Biederman J, et al. A Controlled Study of Nortriptyline in Children and Adolescents With Attention Deficit Hyperactivity Disorder. <i>J Child Adolesc Psychopharmacol.</i> 2000;10(3):193-204.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/11052409/pubmed" id="11052409" target="_blank">11052409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22683887">
<a name="22683887"></a>Pringsheim T, Davenport W, Mackie G, et al; Canadian Headache Society Prophylactic Guidelines Development Group. Canadian Headache Society guideline for migraine prophylaxis. <i>Can J Neurol Sci</i>. 2012;39(2)(suppl 2):S1-S59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/22683887/pubmed" id="22683887" target="_blank">22683887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15534159">
<a name="15534159"></a>Prochazka AV, Kick S, Steinbrunn C, Miyoshi T, Fryer GE. A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation. <i>Arch Intern Med</i>. 2004;164(20):2229-2233. doi:10.1001/archinte.164.20.2229<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/15534159/pubmed" id="15534159" target="_blank">15534159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9778204">
<a name="9778204"></a>Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA, Lofaso D. A randomized trial of nortriptyline for smoking cessation. <i>Arch Intern Med</i>. 1998;158(18):2035-2039. doi:10.1001/archinte.158.18.2035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/9778204/pubmed" id="9778204" target="_blank">9778204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22638709">
<a name="22638709"></a>Rabenda V, Nicolet D, Beaudart C, Bruyère O, Reginster JY. Relationship between use of antidepressants and risk of fractures: a meta-analysis. <i>Osteoporos Int</i>. 2013;24(1):121-137. doi:10.1007/s00198-012-2015-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/22638709/pubmed" id="22638709" target="_blank">22638709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12370455">
<a name="12370455"></a>Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. <i>Neurology</i>. 2002;59(7):1015-1021.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/12370455/pubmed" id="12370455" target="_blank">12370455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15001975">
<a name="15001975"></a>Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants and the risk of sudden cardiac death. <i>Clin Pharmacol Ther</i>. 2004;75(3):234-241. doi:10.1016/j.clpt.2003.09.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/15001975/pubmed" id="15001975" target="_blank">15001975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19209119">
<a name="19209119"></a>Reeves RR, Brister JC. Serious suicide attempt with duloxetine treatment. <i>South Med J</i>. 2008;101(7):769. doi:10.1097/SMJ.0b013e318177872f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/19209119/pubmed" id="19209119" target="_blank">19209119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20443647">
<a name="20443647"></a>Richa S, Yazbek JC. Ocular adverse effects of common psychotropic agents: a review. <i>CNS Drugs</i>. 2010;24(6):501-526. doi:10.2165/11533180-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/20443647/pubmed" id="20443647" target="_blank">20443647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17242321">
<a name="17242321"></a>Richards JB, Papaioannou A, Adachi JD, et al; Canadian Multicentre Osteoporosis Study Research Group. Effect of selective serotonin reuptake inhibitors on the risk of fracture. <i>Arch Intern Med</i>. 2007;167(2):188-194. doi:10.1001/archinte.167.2.188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/17242321/pubmed" id="17242321" target="_blank">17242321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Riedel.1">
<a name="Riedel.1"></a>Riedel W, van Praag HM. Avoiding and managing anticholinergic effects of antidepressants. <i>CNS Drugs</i>. 1995;3(4):245-259.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28769859">
<a name="28769859"></a>Riediger C, Schuster T, Barlinn K, Maier S, Weitz J, Siepmann T. Adverse effects of antidepressants for chronic pain: A systematic review and meta-analysis. <i>Front Neurol</i>. 2017;8:307. doi:10.3389/fneur.2017.00307<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/28769859/pubmed" id="28769859" target="_blank">28769859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22659406">
<a name="22659406"></a>Rizzoli R, Cooper C, Reginster JY, et al. Antidepressant medications and osteoporosis. <i>Bone</i>. 2012;51(3):606-613. doi:10.1016/j.bone.2012.05.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/22659406/pubmed" id="22659406" target="_blank">22659406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9159697">
<a name="9159697"></a>Rollman BL, Block MR, Schulberg HC. Symptoms of major depression and tricyclic side effects in primary care patients. <i>J Gen Intern Med</i>. 1997;12(5):284-291. doi:10.1046/j.1525-1497.1997.012005284.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/9159697/pubmed" id="9159697" target="_blank">9159697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6407505">
<a name="6407505"></a>Roos JC. Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine. <i>Br J Clin Pharmacol</i>. 1983;15 Suppl 3(Suppl 3):439S-445S. doi:10.1111/j.1365-2125.1983.tb02135.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/6407505/pubmed" id="6407505" target="_blank">6407505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6277997">
<a name="6277997"></a>Roose SP, Glassman AH, Siris SG, Walsh BT, Bruno RL, Wright LB. Comparison of imipramine- and nortriptyline-induced orthostatic hypotension: a meaningful difference.<i> J Clin Psychopharmacol</i>. 1981;1(5):316-319. doi:10.1097/00004714-198109000-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/6277997/pubmed" id="6277997" target="_blank">6277997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3900052">
<a name="3900052"></a>Rubin EH, Biggs JT, Preskorn SH. Nortriptyline pharmacokinetics and plasma levels: implications for clinical practice. <i>J Clin Psychiatry.</i> 1985;46(10):418-424.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/3900052/pubmed" id="3900052" target="_blank">3900052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25735839">
<a name="25735839"></a>Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysis. <i>Br J Clin Pharmacol</i>. 2015;80(2):209-220. Erratum in: Br J Clin Pharmacol. 2015;80(4):921-6. doi:10.1111/bcp.12617<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/25735839/pubmed" id="25735839" target="_blank">25735839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28709467">
<a name="28709467"></a>Sabah KMN, Chowdhury AW, Islam MS, Saha BP, Kabir SR, Kawser S. Amitriptyline-induced ventricular tachycardia: a case report. <i>BMC Res Notes</i>. 2017;10(1):286. doi:10.1186/s13104-017-2615-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/28709467/pubmed" id="28709467" target="_blank">28709467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16683860">
<a name="16683860"></a>Schatzberg AF, Blier P, Delgado PL, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. <i>J Clin Psychiatry</i>. 2006;67(Suppl 4):27-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/16683860/pubmed" id="16683860" target="_blank">16683860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33358964">
<a name="33358964"></a>Schoretsanitis G, Westin AA, Stingl JC, Deligiannidis KM, Paulzen M, Spigset O. Antidepressant transfer into amniotic fluid, umbilical cord blood &amp; breast milk: a systematic review &amp; combined analysis.<i> Prog Neuropsychopharmacol Biol Psychiatry</i>. 2021;107:110228. doi:10.1016/j.pnpbp.2020.110228<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/33358964/pubmed" id="33358964" target="_blank">33358964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15014601">
<a name="15014601"></a>Shelton RC. Steps following attainment of remission: discontinuation of antidepressant therapy. <i>Prim Care Companion J Clin Psychiatry</i>. 2001;3(4):168-174. doi:10.4088/pcc.v03n0404<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/15014601/pubmed" id="15014601" target="_blank">15014601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35037597">
<a name="35037597"></a>Sherafat A, Sahebnasagh A, Rahmany R, Mohammadi F, Saghafi F. The preventive effect of the combination of atorvastatin and nortriptyline in migraine-type headache: a randomized, triple-blind, placebo-controlled trial. <i>Neurol Res</i>. 2022;44(4):311-317. doi:10.1080/01616412.2021.1981105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/35037597/pubmed" id="35037597" target="_blank">35037597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8919704">
<a name="8919704"></a>Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. <i>J Am Acad Child Adolesc Psychiatry</i>. 1996;35(4):409-432.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/8919704/pubmed" id="8919704" target="_blank">8919704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26204124">
<a name="26204124"></a>Sriraman NK, Melvin K, Meltzer-Brody S. ABM Clinical Protocol #18: use of antidepressants in breastfeeding mothers. <i>Breastfeed Med</i>. 2015;10(6):290-299.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/26204124/pubmed" id="26204124" target="_blank">26204124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31113373">
<a name="31113373"></a>Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. <i>J Headache Pain</i>. 2019;20(1):57. doi:10.1186/s10194-018-0899-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/31113373/pubmed" id="31113373" target="_blank">31113373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18759711">
<a name="18759711"></a>Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. <i>Expert Opin Drug Saf</i>. 2008;7(5):587-596. doi:10.1517/14740338.7.5.587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/18759711/pubmed" id="18759711" target="_blank">18759711</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Sweetman S, ed. <i>Martindale: The Complete Drug Reference.</i> 37th ed. New York: NY: Pharmaceutical Press; 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16934334">
<a name="16934334"></a>Szanto K, Mulsant BH, Houck PR, et al. Emergence, persistence, and resolution of suicidal ideation during treatment of depression in old age. <i>J Affect Disord</i>. 2007;98(1-2):153-161. doi:10.1016/j.jad.2006.07.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/16934334/pubmed" id="16934334" target="_blank">16934334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19254516">
<a name="19254516"></a>Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. <i>J Clin Psychiatry</i>. 2009;70(3):344-353. doi:10.4088/jcp.07m03780<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/19254516/pubmed" id="19254516" target="_blank">19254516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25921377">
<a name="25921377"></a>Talley NJ, Locke GR, Saito YA, et al. Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study. <i>Gastroenterology</i>. 2015;149(2):340-9.e2. doi:10.1053/j.gastro.2015.04.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/25921377/pubmed" id="25921377" target="_blank">25921377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tauben.1">
<a name="Tauben.1"></a>Tauben D, Stacey BR. Pharmacologic management of chronic non-cancer pain in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 22, 2022.</div>
</li>
<li>
<div class="reference">
                  Taylor FR. Tension-type headache in adults: preventive treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 3, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-induced arrhythmias: A scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS). Smoking cessation. A report of the Surgeon General. <a href="https://www.hhs.gov/sites/default/files/2020-cessation-sgr-full-report.pdf" target="_blank">https://www.hhs.gov/sites/default/files/2020-cessation-sgr-full-report.pdf</a>. Updated 2020. Accessed June 15, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VADoD.1">
<a name="VADoD.1"></a>US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of major depressive disorder. <a href="https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf</a>. Updated February 2022. Accessed June 15, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11250852">
<a name="11250852"></a>van Eijk ME, Avorn J, Porsius AJ, de Boer A. Reducing prescribing of highly anticholinergic antidepressants for elderly people: randomised trial of group versus individual academic detailing. <i>BMJ</i>. 2001;322(7287):654-657. doi:10.1136/bmj.322.7287.654<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/11250852/pubmed" id="11250852" target="_blank">11250852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15906018">
<a name="15906018"></a>van Geffen EC, Hugtenburg JG, Heerdink ER, van Hulten RP, Egberts AC. Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. <i>Eur J Clin Pharmacol</i>. 2005;61(4):303-307. doi:10.1007/s00228-005-0921-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/15906018/pubmed" id="15906018" target="_blank">15906018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31241819">
<a name="31241819"></a>Venkatesan T, Levinthal DJ, Tarbell SE, et al. Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association. <i>Neurogastroenterol Motil</i>. 2019;31(suppl 2):e13604. doi:10.1111/nmo.13604<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/31241819/pubmed" id="31241819" target="_blank">31241819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18219438">
<a name="18219438"></a>Vestergaard P, Rejnmark L, Mosekilde L. Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. <i>Calcif Tissue Int</i>. 2008;82(2):92-101. doi:10.1007/s00223-007-9099-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/18219438/pubmed" id="18219438" target="_blank">18219438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30775508">
<a name="30775508"></a>Wadhwa R, Kumar M, Talegaonkar S, Vohora D. Serotonin reuptake inhibitors and bone health: A review of clinical studies and plausible mechanisms. <i>Osteoporos Sarcopenia.</i> 2017;3(2):75-81. doi:10.1016/j.afos.2017.05.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/30775508/pubmed" id="30775508" target="_blank">30775508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15908090">
<a name="15908090"></a>Wagner KD. Pharmacotherapy for Major Depression in Children and Adolescents. <i>Prog Neuropsychopharmacol Biol Psychiatry.</i> 2005;29(5):819-826.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/15908090/pubmed" id="15908090" target="_blank">15908090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wald.1">
<a name="Wald.1"></a>Wald A. Treatment of irritable bowel syndrome in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 26, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1955276">
<a name="1955276"></a>Walker EA, Roy-Byrne PP, Katon WJ, Jemelka R. An open trial of nortriptyline in women with chronic pelvic pain.<i> Int J Psychiatry Med.</i> 1991;21(3):245-252. doi:10.2190/EXRP-J206-CBWT-UTFK<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/1955276/pubmed" id="1955276" target="_blank">1955276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22936860">
<a name="22936860"></a>Waring WS. Clinical use of antidepressant therapy and associated cardiovascular risk. <i>Drug Healthc Patient Saf</i>. 2012;4:93-101. doi:10.2147/DHPS.S28804<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/22936860/pubmed" id="22936860" target="_blank">22936860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16913164">
<a name="16913164"></a>Warner CH, Bobo W, Warner C, Reid S, Rachal J. Antidepressant discontinuation syndrome. <i>Am Fam Physician</i>. 2006;74(3):449-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/16913164/pubmed" id="16913164" target="_blank">16913164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9781549">
<a name="9781549"></a>Watson CP, Vernich L, Chipman M, Reed K. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. <i>Neurology</i>. 1998;51(4):1166-1171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/9781549/pubmed" id="9781549" target="_blank">9781549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15169695">
<a name="15169695"></a>Weissman AM, Levy BT, Hartz AJ, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. <i>Am J Psychiatry</i>. 2004;161(6):1066-1078.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/15169695/pubmed" id="15169695" target="_blank">15169695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8936916">
<a name="8936916"></a>Wilens TE, Biederman J, Baldessarini RJ, et al. Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents.<i> J Am Acad Child Adolesc Psychiatry</i>. 1996;35(11):1491-1501. doi:10.1097/00004583-199611000-00018.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/8936916/pubmed" id="8936916" target="_blank">8936916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8444763">
<a name="8444763"></a>Wilens TE, Biederman J, Geist DE, Steingard R, Spencer T. Nortriptyline in the treatment of ADHD: a chart review of 58 cases. <i>J Am Acad Child Adolesc Psychiatry</i>. 1993;32(2):343-349.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/8444763/pubmed" id="8444763" target="_blank">8444763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9230637">
<a name="9230637"></a>Wisner KL, Perel JM, Peindl KS, Findling RL, Hanusa BH. Effects of the postpartum period on nortriptyline pharmacokinetics. <i>Psychopharmacol Bull</i>. 1997;33(2):243-248.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/9230637/pubmed" id="9230637" target="_blank">9230637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29536616">
<a name="29536616"></a>Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. <i>Bipolar Disord</i>. 2018;20(2):97-170. doi: 10.1111/bdi.12609.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/29536616/pubmed" id="29536616" target="_blank">29536616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19701065">
<a name="19701065"></a>Yonkers KA, wiser KL, Stewart DE, et al. The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists. <i>Obstet Gynecol</i>. 2009;114(3):703-713. doi: 10.1097/AOG.0b013e3181ba0632.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/19701065/pubmed" id="19701065" target="_blank">19701065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9186793">
<a name="9186793"></a>Yoshida K, Smith B, Craggs M, Kumar RC. Investigation of pharmacokinetics and of possible adverse effects in infants exposed to tricyclic antidepressants in breast-milk. <i>J Affect Disord</i>. 1997;43(3):225-237.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/9186793/pubmed" id="9186793" target="_blank">9186793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25065442">
<a name="25065442"></a>Zimmermann-Viehoff F, Kuehl LK, Danker-Hopfe H, Whooley MA, Otte C. Antidepressants, autonomic function and mortality in patients with coronary heart disease: data from the Heart and Soul Study. <i>Psychol Med</i>. 2014;44(14):2975-2984. doi:10.1017/S003329171400066X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nortriptyline-pediatric-drug-information/abstract-text/25065442/pubmed" id="25065442" target="_blank">25065442</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12653 Version 510.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
